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SUMMARY 
Global Health Initiatives (GHIs) originated in 1978 at the Alma Ata conference.  The Alma Ata 
Declaration of Health for all by the year 2000 supported a comprehensive package of services to 
address child health, prevention and control of diseases and immunization against communicable 
diseases. In 1982, Comprehensive primary health care was replaced by UNICEF’s Declaration of a 
Children’s Revolution, which supported selective primary care and emphasized priority diseases, 
including malaria, and a package of cost effective interventions, such as immunization.  
A key component of child health is availability and access to immunization. Traditionally, it takes 
years and decades for interventions and vaccines to become available and accessible to those most 
in need.  Two major reasons for these delays are insufficient anticipation of the policy process and 
the absence of a framework to facilitate a comprehensive understanding of policy process required 
for decision making.   
This thesis describes research into anticipated policy processes and develops a comprehensive 
framework for informing policy decisions about the RTS,S malaria vaccine in Tanzania. RTS,S is the 
most advanced of malaria vaccines in development and has shown to protect children 5-17 months 
when used in conjunction with other malaria control strategies such as insecticides treated nets 
(ITNs) and anti-malaria drugs.  
National policy decisions for introducing new malaria interventions and vaccines are shaped by global 
health policies. This is the case for the malaria vaccine RTS,S will be implemented at national level 
after the approval of WHO global recommendations. The policy process is time consuming, involves 
several steps and consideration of several factors before settling on a decision. Early planning is 
essential to having a clear picture of decision making steps and the policy context in which a malaria 
vaccine might be implemented.   
The goal of this study was to analyse the decision making and policy development process for 
introducing new malaria interventions in Tanzania, without any precedent of malaria vaccine use that 
might help to understand the context in which a malaria vaccine could be implemented. The goal was 
pursued using the following methods: a cross-sectional study, a qualitative approach and a synthesis 
approach. A cross-sectional study of 23 regions of Tanzania conducted during the Tanzanian 
Integrated Measles Campaign (IMC) survey in 2011 assessed awareness of and willingness to use a 
malaria vaccine among women aged 18 years or older with children under 11 months old. The main 
outcome measure was willingness to use a malaria vaccine. Document review and in-depth 
interviews with 20 key informants were conducted to assess malaria treatment policy changes in 
Tanzania and in other African RTS,S study countries.  A comparative table and framework analysis 
was used as a practical guide to the steps of the decision making and policy process validated in 
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Tanzania and other African RTS,S study countries.  Synthesis and analysis of the results obtained from 
those studies were used to propose practical recommendations for malaria vaccine implementation. 
The main findings were as follows: 
 A high willingness to use the malaria vaccine, associated with a high level of knowledge of 
the benefits of vaccinating children under-five, high acceptance of the mode of administering 
the malaria vaccine (2-3 injected doses delivered in the same day according to the proposed 
schedule for receiving the malaria vaccine). 
 The framework was developed and applied to RTS, S African countries with regard to its 
readiness for adoption of the forthcoming malaria vaccine. The rating implies that Tanzania 
((12), very good), Burkina Faso ((10), Malawi (9), Kenya and Gabon (8), good) are prepared —
with regard to policy promoting factors —to embark on adopting the forthcoming malaria 
vaccine, RTS, S. Ghana  ((5), little) has few policy promoting factors in place and had not yet 
documented information on barriers to decision making. Mozambique ((1), weak) had hardly 
documented any promoting factors or barriers. The attempt to compare showed some 
“good” and “very good” rankings regarding policy promoting factors although these factors 
may be hindered by some mentioned and documented barriers. 
According to the findings, implementing the RTS,S malaria vaccine in programme settings still 
requires guidance in the form of proposed recommendations: 
In Tanzania, the malaria vaccine is expected to be delivered through Immunization and Vaccine 
Development (IVD), and implemented at facility level by health care providers in both private and 
public facilities.  In order to support and propagate the policy, a number of activities are 
recommended. For example, awareness should be created through developing a package of 
information for the community, the consumers of the vaccine that is accessible and offered in user 
friendly settings.  Different types of media could be used for vaccine adverts and advocacy.  A 
partnership between IVD and Global Alliance on Vaccine Initiative (GAVI) would help to ensure that 
the vaccine is delivered on time. IVD should strengthen its storage capacity to accommodate the 
malaria vaccine.  To prepare for financing the vaccine, co-financing levels should be incorporated into 
the national budget. Guidelines, documents and training materials for immunization services should 
be modified to include the malaria vaccine.  Health care personnel involved in vaccination should 
receive necessary training and a special surveillance system should be established to monitor vaccine 
pharmacovigilance both at national and district levels.  
Implementing RTS,S in programme settings still requires some research into: i) assessing the 
packaging of RTS,S and the storage capacity of IVD to accommodate the malaria vaccine;  ii) assessing 
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vaccine pharmacovigilance in low and high transmission settings; iii)  identifying the required 
numbers and skills of human resources iv) determining the additional workload for health care 
workers involved in vaccination.   
This is the first report evaluating the policy and decision making process for introducing a malaria 
vaccine in Tanzania, without any precedent of malaria vaccine use. The results contribute to the 
growing knowledge that understanding people’s perceptions of a new malaria vaccine and the 
availability of a comprehension framework to understanding the policy process could  speed up the 
decision making process and shorten the time needed to make the vaccine available to those in 
need.  However, RTS, S vaccine alone does not provide a definitive solution to preventing malaria. 
The vaccine should be integrated with other strategies to address the burden of malaria in malaria 
endemic countries in Africa.  These findings would be useful for other African countries planning to 
embark on implementing the RTS,S malaria vaccine when global RTS, S policy recommends its use.  
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ZUSAMMENFASSUNG 
Die Global Health Initiatives (GHIs) wurden im Jahr 1978 während der Alma-Ata Konferenz 
gegründet. Die Deklaration von Alma-Ata über „Gesundheit für Alle“ bis zum Jahr 2000 förderte ein 
umfassendes Packet von Leistungen fokussierend auf Gesundheit von Kindern, Prävention und 
Kontrolle von Krankheiten, sowie Impfungen gegen Infektionskrankheiten. Im Jahr 1982 wurde die 
flächendeckende Basisgesundheitsversorgung durch die „UNICEF Declaration of a Children‘s 
Revolution“ ersetzt, welche eine selektive medizinische Grundversorgung unterstützte, sich auf 
priorisierte Krankheiten, einschliesslich Malaria, konzentrierte und zahlreiche kostengünstige 
Interventionen, wie Immunisierung, förderte. 
Ein Schlüsselelement in der Gesundheit von Kindern ist Zugang zu und Verfügbarkeit von Impfungen. 
Ehrfahrungsweise dauert es oft Jahre bis Jahrzehnte, bis solche Interventionen und Impfprogramme 
denen, die sie am dringendsten benötigen, zur Verfügung gestellt werden. Hauptgründe für diese 
Verzögerungen liegen oft bei ungenügender Planung im politischen Prozess und dem Fehlen von 
Rahmenbedingungen, welche die Entscheidungsfindung erleichtern würden. 
Diese Dissertation beschreibt das Erforschen von antizipierten politischen Prozessen und entwickelt 
umfassende Rahmenbedingungen zur Information der Grundsatzentscheidung in Bezug auf den 
Malaria-Impfstoff RTS, S in Tansania. RTS,S ist der zur Zeit am weitesten entwickelte Impfstoff gegen 
Malaria. Tests zeigen einen wirkungsvollen Impfschutz bei Kindern im Alter von 5-17 Monaten, wenn 
die Impfung in Verbindung mit weiteren Malariakontrollstrategien, wie Insektizid-behandelten 
Moskitonetzen (ITNs) und Anti-Malaria Medikamenten, angewendet wird. 
Nationale Grundsatzentscheidungen für die Einführung von neuen Malaria Interventionen und 
Impfstoffen basieren auf globalen Gesundheitsstrategien. Dies ist auch der Grund warum die 
Malaria-Impfung RTS,S nach der Zulassung durch die WHO auf nationaler Ebene eingeführt wird. 
Dieser politische Prozess ist nicht nur zeitintensiv, sondern beinhaltet auch mehrere Stufen bezüglich 
des Abwägens von verschiedenen Faktoren, bevor eine finale Entscheidung getroffen werden kann. 
Eine frühzeitige Planung ist daher entscheidend. Sie erlaubt es, ein klares Bild über den 
Entscheidungsfindungs-Prozess und den politischen Kontext zu erstellen, in welchen die Malaria-
Impfung eingeführt werden soll. 
Das Ziel dieser Arbeit war es, die Entscheidungsbildung und den Prozess der Strategie-Entwicklung 
für die Einführung von neuen Malaria Interventionen in Tansania zu analysieren, ohne vorangehende 
Anwendung einer Malaria-Impfung, was den Kontext besser verständlich machen könnte, in 
welchem die Malaria-Impfung eingeführt werden soll. Dieses Ziel wurde durch die Anwendung 
folgender Methoden angestrebt: Eine Querschnittsstudie, eine qualitative und eine darstellende 
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Methode. Die Querschnittsstudie wurde während der „Tanzanian Integrated Measles Campaign“ 
(IMC) Umfrage im Jahr 2011 in 23 Regionen Tansanias durchgeführt, um abzuschätzen, ob Mütter ab 
18 Jahren oder älter mit Kindern unter 11 Monaten über eine derartige Schutzimpfung Bescheid 
wissen und zu bereit wären sich impfen zu lassen. Eine Dokumenten-Recherche und individuelle 
Interviews mit 20 Schlüsselpersonen wurden durchgeführt, um Entwicklungen der Malaria 
Behandlungsstrategien in Tanzania und anderen RTS,S-Studien Ländern in Afrika zu erheben. Als 
praktischer Leitfaden zu den Etappen der Entscheidungsfindung und den politischen Prozessen 
dienten eine Vergleichstabelle und die Analyse der Rahmenbedingungen, welche in Tanzania und 
anderen afrikanischen RTS,S Studien Ländern validiert wurden. Die Synthese und Analyse der 
Resultate, aus diesen Studien gewonnen, wurden angewendet, um praktische Befürwortung zur 
Einführung einer Malaria-Impfung zu erarbeiten. Im Folgenden werden die wichtigsten Ergebnisse 
aufgelistet: 
 Es besteht eine große Bereitschaft zur Anwendung der Malaria-Impfung, assoziiert mit einem 
hohen Grad an Wissen um die Vorteile des Impfens von Kindern unter fünf Jahren und einer 
hohen Akzeptanz der Verabreichungsform von der Impfung (2-3 Injektionen an einem Tag, 
gemäß des empfohlenen Impfschemas). 
 Im Hinblick auf die bevorstehende Einführung der Malaria-Impfung wurde das 
Rahmenprogramm für die afrikanischen RTS,S Länder angepasst und angewandt. Die 
Bewertung besagt, dass Tansania ((12), sehr gut), Burkina Faso ((10), Malawi (9), Kenia und 
Gabun (8), gut) - in Bezug auf Strategie-fördernder Faktoren -  vorbereitet sind, um die 
Einführung der Malaria-Impfung RTS,S zu starten. Ghana (5), klein) konnte nur wenige 
Strategie-fördernden Faktoren vorweisen und es fehlt auch noch die Dokumentation der 
Hindernisse zur Entscheidungsfindung. Ebenso konnte Mozambique (schwach) noch keine 
entsprechende Dokumentation vorlegen. Der Vergleichs-Ansatz zeigte zwar einige „gute“ 
und „sehr gute“ Bewertungen bezüglich Strategie-fördernder Faktoren, jedoch könnten diese 
durch die oben erwähnten und dokumentierten Barrieren geschmälert werden. 
In Übereinstimmung mit den Ergebnissen verlangt die Einführung der RTS,S Malaria-Impfung im 
Programm-Umfeld dennoch Richtlinien in der Form der hier vorgeschlagenen Empfehlungen: 
In Tansania wird die Malaria-Impfung erwartungsgemäß über IVD (Immunization and Vaccine 
Development) geliefert und anschließend in staatlichen und privaten Gesundheits-Einrichtungen 
durchgeführt. Um dieses Vorhaben zu unterstützen und zu propagieren werden einige Tätigkeiten 
empfohlen. Zum Beispiel sollte die Bevölkerung durch ein Informationspacket aufmerksam gemacht 
werden, welches leicht zugänglich sein sollte. Verschiedene Medien sollten für die Ankündigung und 
Befürwortung der Impfung eingesetzt werden. Eine Partnerschaft zwischen IVD und GAVI wäre 
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hilfreich, um eine zeitgenaue Lieferung der Impfstoffe zu garantieren. Ebenso sollte IVD seine 
Lagerkapazität erhöhen. Für die Finanzierung der Impfung sollten im nationalen Budget co-
Finanzierungslevels integriert werden. Richtlinien, Dokumente und Ausbildungsmaterialen für Impf-
Dienstleister sollten entsprechend modifiziert werden und um die Malaria-Impfung ergänzt werden. 
Impfendes Gesundheitspersonal sollte die nötige Ausbildung erhalten und ein spezielles Monitoring-
System sollte etabliert werden, um die Pharmakovigilanz auf Bezirks- und auf nationaler Ebene zu 
überwachen. 
Die Einführung von RTS,S in Programm-Settings benötigt dennoch weitere Forschung: i) Abschätzen 
der Packungseinheit von RTS,S und der Lagerkapazität des IVD, welcher die Malaria-Impfung lagern 
wird; ii) Einschätzung der Pharmakovigilanz in Gebieten mit hohen und tiefen Übertragungsraten; iii) 
Ermittlung des Personalbedarfs und der notwendigen Fähigkeiten des Personals; iv) Abschätzen des 
durch die Malaria-Impfung entstehenden Mehraufwandes für das Gesundheitspersonal. 
Dies ist der erste Evaluationsbericht über Strategieentwicklung und Entscheidungsfindungsprozesse 
für die Einführung einer Malaria-Impfung in Tansania, ohne vorangehende Anwendung einer Malaria-
Impfung. Die Resultate tragen zum wachsenden Wissen über Verständnis und Wahrnehmung einer 
neuen Malaria-Impfung in der Bevölkerung bei und zeigen, dass die Verfügbarkeit von umfassenden 
Rahmenbedingungen zur Information und zum Verständnis der politischen Prozesse die 
Entscheidungsfindung beschleunigen, und die benötigte Zeit somit verkürzen, um die Impfung für die 
bedürftige Bevölkerung zur Verfügung zu stellen. Natürlich kann RTS,S alleine keine definitive Lösung 
zur Malariaprävention bieten. Deshalb sollte die Impfung  in andere Strategien eingebunden werden, 
um die Krankheitslast durch Malaria in endemischen Ländern in Afrika zu minimieren. Diese 
Ergebnisse sind für weitere afrikanische Länder wichtig, welche den Start einer Malaria-Impfung mit 
RTS,S planen, wenn die globale RTS,S Strategie ihre Anwendung empfiehlt. 
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MUHTASARI 
Harakati za kimataifa za afya zilianza mnamo mwaka 1978 katika mkutano wa Alma Ata. Azimio la 
Afya kwa wote ifikapo mwaka 2000 la Alma Ata  liliunga mkono  mipango mipana ya jumla ya 
huduma za kushughulikia afya ya mtoto, kinga na kudhibiti magonjwa na kinga dhidi ya magonjwa ya 
kuambukiza. Mnamo mwaka 1982, huduma ya afya ya msingi iliondolewa kupisha Azimio la UNICEF 
la Mapinduzi ya Watoto ambayo inaunga mkono huduma za msingi zilizochaguliwa na kusisitiza 
magonjwa ya kipaumbele yakiwemo malaria, na mpango wa jumla wa gharama halisi za utatuzi  
kama vile kinga. 
Sehemu kuu ya afya ya mtoto ni upatikanaji na ufukiaji wa kinga. Kimazoea, huchukua miaka na 
miongo kwa mipango ya utatuzi na chanjo ili iweze kufikika kwa wale haswa wenye kuihitaji. Sababu 
kuu mbili kwa ucheleweshwaji huu ni upungufu wa dhana ya mchakato wa sera na kukosekana kwa 
mpangilio wa kuwezesha uelewa wa jumla wa mchakato wa sera unaohitajika kwa ufanyaji maamuzi. 
Tasnifu hii inaelezea utafiti ndani ya dhana ya mchakato wa sera na kuendeleza mpangilio mpana 
kwa ajili ya kuelezea maamuzi  ya sera kuhusu chanjo ya malaria ya RTS,S katika Tanzania. RTS,S  
chanjo ya malaria iliyopiga hatua katika maendeleo na imeonesha kukinga watoto kati ya miezi 5-17 
inapotumika pamoja na mikakati mingine ya kudhibiti malaria kama vile vyandarua vilivyotiwa dawa 
(ITNs) na dawa za kutibu malaria. 
Maamuzi ya sera ya taifa ya kuanzisha tatuzi (intervention) mpya za malaria na chanjo yanaongozwa 
na sera za afya za dunia. Hii ndivyo ilivyo kwa chanjo ya malaria. RTS,S itatekelezwa katika ngazi ya 
kitaifa baada ya  kuidhinishwa kwa mapendekezo ya dunia ya Shirika la Afya Duniani (WHO). 
Mchakato wa sera hutumia muda mrefu, ikijumuisha hatua kadhaa na uzingatiaji wa sababu kadhaa 
kabla ya kufikia uamuzi. Mpango wa mapema ni muhimu ili kuwa na picha halisi ya hatua za ufanyaji 
uamuzi na maudhui ya sera ambayo chanjo ya malaria itakuwa inatekelezwa. 
Lengo la utafiti huu ilikuwa ni kuchambua mchakato wa ufanyaji maamuzi na uendelezaji sera kwa 
ajili ya kuanzisha tatuzi mpya za malaria katika Tanzania, pasipo kutumia chanjo yoyote ya malaria 
iliyotangulia ambayo inaweza kusaidia kuelewa maudhui ambayo chanjo ya malaria itatekelezwa. 
Lengo lilishikiliwa kwa kutumia njia zifuatazo: utafiti wa mara moja, wa njia za kujieleza au simulizi na 
unganishi. Utafiti wa mara moja wa mikoa 23 ya Tanzania uliofanyika wakati wa  utafiti wa kampeni 
ya pamoja ya surua (IMC) katika mwaka 2011 ukitathmini ufahamu wa, na utayari wa kutumia chanjo 
ya malaria miongoni mwa wanawake wenye umri wa miaka 18 au zaidi wenye watoto chini ya miezi 
11. Matokeo makuu  ilikuwa ni utayari wa kutumia chanjo ya malaria. Upitiaji nyaraka na mahojiano 
ya kina na watoa taarifa wakuu 20 yalifanyika kutathmini mabadiliko ya sera ya kutibu malaria katika 
Tanzania na nchi nyingine za utafiti wa RTS,S. Jedwali linganishi na mpangilio wa uchambuzi ulitumika 
kama mwongozo wa vitendo katika hatua za ufanyaji maamuzi na kuhalalisha au kuthibitisha 
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mchakato wa sera katika Tanzania na nchi nyingine za kiafrika za utafiti wa RTS,S. Uunganishaji na 
uchambuzi wa matokeo yaliyopatikana kutoka tafiti hizo yalitumika kupendekeza mapendekezo ya 
vitendo kwa utekelezaji wa chanjo ya malaria. Matokeo makuu yalikuwa kama ifuatavyo: 
  Utayari wa hali ya juu wa kutumia chanjo ya malaria, ikihusiana na kiwango kikubwa cha 
ujuzi wa faida za chanjo kwa watoto chini ya umri wa miaka mitano, kukubalika kwa hali ya 
juu kwa muundo wa utoaji chanjo ya malaria (utoaji dozi 2-3 kwa siku moja kutokana na 
ratiba itakayopendekezwa ya upokeaji chanjo ya malaria) 
  Mpangilio uliigwa na kufanyiwa mabadiliko na kutumika katika nchi za RTS,S kwa kuzingatia 
utayari wake wa kuiga chanjo ijayo ya malaria kama ilivyo. Ukadiriaji unaashiria kwamba 
Tanzania ((12), nzuri sana), Burkina Faso ((10), Malawi (9), Kenya na Gabon (8), nzuri) 
zinaandaliwa kwa kuzingatia sababu za undelezaji sera kuingia katika uigaji chanjo ya malaria 
ijayo, RTS,S.  Ghana (5), kidogo) ina sababu za undelezaji sera chache zilizopo na haijaweka 
katika kumbukumbu taarifa kuhusu vikwazo katika ufanyaji maamuzi. Msumbiji ((1), dhaifu) 
ina kumbukumbu chache za sababu zozote za uendelezaji au vikwazo.  Jaribio la kulinganisha 
imeonesha  viwango vya “vizuri” na “vizuri sana” kuzingatia sababu za uendelezaji sera 
ingawa sababu hizi zinaweza kuzuiwa na baadhi ya vikwazo vilivyotajwa na vilivyopo katika 
kumbukumbu. 
Kutokana na matokeo, utekelezaji wa chanjo ya RTS,S  katika mpango ulioandaliwa, bado unahitaji 
mwongozo katika muundo wa mapendekezo yaliyopendekezwa 
Katika Tanzania, chanjo hii ya malaria inatarajiwa kutolewa kupitia mpango wa Kinga na Uendelezaji 
chanjo (IVD) na kutekelezwa katika ngazi ya kituo cha tiba na watoa huduma katika vituo vyote vya 
binafsi na umma. Ili kuunga mkono na kuendeleza sera hii, baadhi ya shughuli zimependekezwa. Kwa 
mfano, ufahamu uanzishwe kupitia uendelezaji wa mpango wa jumla wa taarifa kwa jamii, watumiaji 
wa chanjo hii ambayo inafikika na kutolewa katika mazingira rafiki. Aina tofauti za njia zinaweza 
kutumika katika kutangaza na kuendeleza chanjo. IVD iimarishe uwezo wake wa kuhifadhi ili kukidhi 
chanjo hii. Ushirikiano baina ya IVD na Ushirika wa kimataifa wa mkakati wa chanjo (GAVI) utasaidia 
kuhakikisha kwamba chanjo hii inatolewa kwa wakati. Kuandaa utoaji fedha kwa ajili ya chanjo hii, 
ngazi za pamoja za utoaji fedha zitajumuishwa katika bajeti ya kitaifa. Miongozo, nyaraka na vifaa vya 
mafunzo kwa ajili ya   huduma za kinga ziboreshwe ili zijumuishe chanjo ya malaria. Watumishi watoa 
huduma za afya watakaojumuishwa katika chanjo wapate mafunzo muhimu na mfumo maalumu wa 
ukusanyaji tarifa au takwimu za afya uanzishwe kufuatilia madhara ya chanjo katika ngazi ya wilaya 
na kitaifa. 
Utekelezaji wa chanjo ya RTS,S katika mpango ulioandaliwa bado unahitaji baadhi ya tafiti katika i) 
kutathmini mpango wa jumla wa RTS,S na uwezo wa kuhifadhi wa IVD kukidhi chanjo hii ya malaria; 
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ii) kutathmini ufuatiliaji wa madhara ya chanjo katika mazingira ya maambukizi ya kiwango cha chini 
na katika kiwango cha juu; iii) kuainisha idadi inayotakiwa na ujuzi wa rasilimali watu iv) kuangalia 
ukubwa wa kazi ya ziada kwa watoa huduma wa afya waliojumuishwa katika chanjo. 
Hii ni ripoti ya kwanza kutathmini sera na mchakato wa ufanyaji maamuzi kwa ajili ya kuanzisha 
chanjo ya malaria katika Tanzania, pasipo kutumia chanjo yoyote iliyotangulia. Matokeo haya 
yatachangia  katika ukuzaji ujuzi wa kuelewa mtazamo wa watu katika chanjo mpya ya malaria na 
upatikanaji wa ufahamu wa mpangilio wa uelewa wa mchakato wa sera hii utaharakisha mchakato 
wa ufanyaji uamuzi na kufupisha muda unaohitajika kufanya chanjo hii kupatikana kwa wale wenye 
kuhitaji. Hata hivyo, RTS,S pekee haitoi ufumbuzi sahihi wa kukinga  malaria. Chanjo hii ijumuishwe 
pamoja na mikakati mingine  kutatua mzigo wa malaria katika nchi zenye malaria kwa muda mrefu 
katika Afrika. Matokeo  haya yatafaa kwa nchi nyingine za kiafrika kupanga kuingia katika utekelezaji 
wa chanjo hii ya malaria ya  RTS,S wakati sera ya dunia ya RTS,S ikipendekeza utumiaji wake. 
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1. Introduction  
This chapter provides background information on the evolution of global health strategies and 
discusses how global health strategies shaped policy surrounding malaria interventions and its 
implications for implementation the forthcoming malaria vaccine. 
1.1 Global Health Strategies  
Global health strategies can be traced back to 1978, when the international conference on Primary 
Health Care (PHC) was held in Alma Ata. The conference expressed to the world the need to protect 
and promote the health of all people. The concept of Comprehensive Primary Health Care (PHC) was 
declared as a strategy to achieve “Health for All 2000” (WHO, UNICEF 1978). The declaration 
supported the basic principles of PHC, based on universal access, equity, participation and an inter-
sectoral approach (WHO, UNICEF 1978; Jong-wook 2003). The components of PHC targeted child 
health, prevention and control of diseases and immunization against communicable diseases, (WHO, 
UNICEF 1978; Osazuwa-Peters 2011). In 1982, comprehensive PHC was replaced by UNICEF’s 
Declaration of a Children’s Revolution, which supported selective PHC, focussing on a package of low 
cost interventions including immunization. Immunization was perceived as a practical intervention 
that was easy to monitor and to evaluate. As a result of the declaration, global immunization 
coverage of children under 1 year increased from 20% in 1980 to 79% by 2006 and  child survival was 
enhanced (Wisner 1988).   
Among the key messages drawn from both the Alma Ata declaration (1978) and UNICEF’s Children’s 
Revolution (1982) initiatives, one is especially relevant to the current question of implementing the 
forthcoming malaria vaccine, and that is child health depends on the availability of and access to 
immunizations. The use of PHC methods, such as outreach and home-based service, is likely to 
increase access to RTS,S and make it affordable in terms of geographical accessibility by the target 
communities that need it most. The world Development Report (1993) emphasizes the need to 
address PHC and to strengthen health systems to reach people in need and improve health outcomes 
(World Bank 1993).   
The World Development Report (1993) “Investing in Health” proposed that health investments are a 
viable strategy for achieving economic development, based on evidence from cost-effective 
interventions to address the burden of disease.  The burden of disease (BOD) is estimated in terms of 
Disability Adjusted Life Years (DALYs) lost and the cost effectiveness of interventions is cost per DALY 
gained. To measure the BOD, the report uses the DALYs as a measure that combines healthy life 
years lost because of pre mature mortality with those lost as a result of disability (World Bank 1993). 
Reducing the burden of infectious diseases such as malaria will increase workforce productivity that 
facilitates investment and enhance economic development (Savigny 2004). 
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The WDR 1993 suggested a minimum package of essential health and PHC interventions that have a  
significant impact on the existing burden of disease while maintaining cost effectiveness (World Bank 
1993).  To implement the report’s recommendations, few studies embarked on health system 
strengthening, one of which yielded  the Tanzania Essential Health Interventions Project (TEHIP) tool 
(Savigny 2004). The tool enabled district health planners to plan and set priorities using the BOD 
profile and cost-effectiveness analysis for resource allocation and expenditure targeting improved 
health systems delivery (Savigny 2004). The TEHIP tool was developed and tested in Rufiji and 
Morogoro districts in Tanzania and achieved various health outcomes, including  reduction of child 
mortality by 40% and increased capacity to health systems in planning and prioritization of local 
burden of disease (Savigny 2004). Planning for the new malaria vaccine should take into account its 
cost effectiveness compared to other existing malaria interventions, to minimize government 
spending while addressing the disease in an efficient way. Including the malaria vaccine in health-
related strategies and aligning policy to the global and national plans to address health-related 
Millennium Development Goals (MDGs) would offer a clear picture of the funding sources available.   
1.1.1 GHIs Progress and Prospects 
In 2000, the United Nations Millennium Declaration was signed to commits world leaders to combat 
poverty, hunger, disease, illiteracy, environmental degradation, and discrimination against women. 
The MDGs are derived from this Declaration, and all have specific targets and indicators 
(www.who.int/topics/millennium_development_goals/en).  Eight MDGs were to be achieved by 
2015. Five of the eight goals targeted health development, including MDG 1 to eradicate extreme 
poverty and hunger; MDG 4 to reduce child mortality by two thirds amongst children under five; 
MDG 5 to reduce maternal mortality by three quarters; MDG 6 to halt and reverse the incidence and 
spread of HIV/AIDS, Malaria and infectious disease; and MDG 8 for global partnership for 
development www.un.org/millenniumgoals/bkgd.shtml.  To achieve health-related MDG targets, 
new actors were needed to deliver health care services, such as the private sector, philanthropic 
trusts, and civil society entities that worked together to create global public private partnerships 
(PPPs). Some of the private and philanthropic actors working in health include the Bill and Melinda 
Gates Foundation, the Clinton Foundation, the Rockefeller Foundation, the Ford Foundation and the 
WK Kellogg Foundation. These organizations worked alongside other disease-oriented global players 
such as the Global Alliance for Vaccines and Immunization (GAVI) and the Global Fund to fight 
HIV/AIDS, Tuberculosis (TB) and malaria (GFATM), World Bank Multi-Country AIDS Program (MAP), 
the US President’s Emergence Plan for AIDS Relief (PERFAR), the US President’s Malaria Initiative 
(PMI), the Stop TB Partnership, and the Roll Back Malaria Partnership among others (World Health 
Organization Maximizing Positive Synergies Collaborative Group et al. 2009; van Olmen et al. 2012). 
The GAVI focuses on childhood immunization while GFATM emphasizes disease-specific 
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programmes, including malaria.  The PPPs fund malaria clinical trials and research and provide 
technical advice that is likely to influence malaria vaccine policy recommendations and its 
implementation at the national level.   
1.1.2 Aid Effectiveness  
GHIs established the international aid framework stipulated by the Paris Declaration on Aid 
Effectiveness (OECD 2005). The framework sought to harmonize donor funds to maximize efficiency 
by mobilizing funds into one basket and allocating funds with a focus on a specific disease or 
intervention. The health outcomes expected from investment in disease-specific programmes or 
interventions depend on better alignment of targeted programmes with health services and 
integration into health systems that contribute to overall health system strengthening (van Olmen et 
al. 2012). Harmonization of global health efforts can ensure that malaria vaccines are addressed in 
the global health agenda and are incorporated into global health plans and activities, thereby 
increasing funding opportunities for the malaria vaccine.  
1.1.2.1 Contextualizing Aid Effectiveness in Tanzania  
The Medium Term Expenditure Framework (MTEF), a budgetary instrument, was developed to 
incorporate planning and financing of the three year work programme for the Ministry of Health, for 
both recurrent and development activities, into one document. The Sector Wide Approach (SWAp) 
was developed as a mechanism by which to maintain sustainable relations with other service 
providers in health and with Development Partners (DPs).  MTEF’s achievement was the introduction 
of the Health Basket Fund, through which Councils receive funds for implementing health activities 
and interventions. The Comprehensive Council Health Plan (CCHP) was introduced as a management 
instrument to understand implementation of councils’ health activities and interventions (Tanzania 
HSSP III 2008). In Tanzania, a limited mechanism of accountability for donor funds exists, which 
monitors and evaluates performance of the funds. A planning tool using MTEF monitors fund 
allocations to ensure they are in line with budget targets. The procedures associated with the flow of 
funds from the Health Basket Fund to the government exchequer system and reallocation to the 
districts or councils could cause delays in malaria vaccine implementation and limit its access to 
those most in need. Availability of a specific framework would be useful for monitoring and 
evaluating donor contributions to implementing interventions. Policy decisions to introduce new 
malaria interventions require evidence-based information that is generated by research.  The need 
for evidence-based decisions was stimulated by a Ministerial summit in Mexico.   
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1.1.3 Research and GHI progress  
The Ministerial Summit on Health Research was held on November 16-20, 2004 and brought 
together health ministers or their representatives from governments in developed and developing 
countries. The summit also included intergovernmental organizations, the private sector, researchers 
and research councils, leaders and users of health research and civil society. Together, they  
discussed how health research could strengthen national health systems to achieve the health-
related  MDGs (WHO Ministerial Summit 2004). Among the key messages drawn from the summit 
were the needs to strengthen health systems and to translate scientific knowledge into evidence- 
based information to aid policy makers deliver targeted interventions to achieve specific health 
outcomes. 
From a health systems thinking perspective, health systems research produces evidence-based 
information that helps to plan and evaluate interventions. The system involves linkages, 
relationships, interactions and behaviours among the elements that constitute the health systems’ 
building blocks. Such building blocks include service delivery, the health workforce, information, 
medical products, vaccines and technologies, financing, and leadership and governance 
(stewardship).  Analysing the root cause of the problem helps to show how the intervention will 
cause reactions in the system and how the system will respond to it.  An intervention that targets 
one health system block will have an effect on other building blocks; this is also called a “system wide 
effect” or “system level interventions” (Savigny D;  Adam T 2009). Applying this concept to the 
forthcoming malaria vaccine policy, malaria vaccination procedures need to be understood, 
immunization guidelines need to be revised and strategies to accommodate the malaria vaccine need 
to be developed. In turn, there will be a demand for in-service training (on revised immunization 
guidelines and strategies), a need to package and disseminate adequate and accurate information for 
the health workers and for users of the vaccine, and a way of funding these activities. In summary, 
addressing a health problem among children through malaria vaccine introduction poses concerns 
about service delivery, health workforce capabilities, information availability and financing.  
Introducing new interventions involve interactions among multiple actors. Applying complex systems 
analysis would help policy makers to identify influential actors and to develop appropriate and timely 
strategies for addressing them.  
1.1.4 Prospects of new technology and stakeholder involvement in the process 
Various stakeholders influence the policy development process at each stage. These stakeholders are 
actors who drive the system through their participation as individuals or groups and their networks; 
their participation supports service delivery that aims to achieve specific health outcomes (Savigny D;  
Adam T 2009). Stakeholders are categorized into different levels: international/global, regional, 
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national, sectoral, district, health facility and community. For the case of RTS,S, the World Health 
Organization (WHO) is responsible for making global policy recommendations and the national 
regulatory authority assesses the vaccine according to the standards set for marketing authorization 
(Joint Technical Expert Group 2009). In Tanzania; Tanzania Food and Drug Authority (TFDA) is the 
regulatory authority that assesses the vaccine according to WHO standards. Other key actors include 
community members, health workers, managers, policy makers, research community representatives 
and funding partners (Tanzania HSSP III 2008). Identifying and understanding the key actors and their 
influence on policy decisions for malaria interventions will facilitate implementation of the 
forthcoming malaria vaccine.  Understanding the status of malaria disease at the global and national 
levels will help to understand how the malaria vaccine can be integrated into other existing malaria 
interventions and strategies, which depend on the current malaria situation in a specific country.   
1.2 Malaria World Wide  
In 2014, the WHO estimated that global malaria mortality rates were reduced by 47% between 2000 
and 2013. These substantial reductions occurred as a result of improved malaria intervention tools, 
increased political commitment and increased international and domestic financing (World Malaria 
Report 2014).   
1.2.1 Malaria in Tanzania 
Due to its geography and climate, Tanzania presents a wide range of malaria transmission levels. 
There are three malaria epidemiological strata in Tanzania. First, the arid central plateau (20% of the 
country) is characterized by unstable and seasonal malaria transmission. Second, the southern part 
of the country with one main rainy season (March –May), and the northern and western parts with 
bimodal rainfall (November –January) are characterized by stable malaria with seasonal variations in 
transmission. Third, the coastal fringe, southern lowlands and Lake Victoria regions are characterized 
by stable malaria with high transmission. Plasmodium falciparum accounts for 96% of all malaria 
infections in Tanzania (World Malaria Report 2012; PMI 2012). Some 31,900,000 people (73% of the 
population) live in high transmission areas. Approximately 11, 800,000 people (27% of the 
population) live in low transmission areas (World Malaria Report 2012). With nearly three quarters of 
the Tanzanian population living in high transmission zones, there is a need to introduce other 
interventions that contribute to the reduction of malaria transmission.  This may be achieved if the 
measures target the source of transmission through malaria vaccines (Graves and Gelband 2006).  
1.2.2 Malaria Control Strategies 
Malaria control programmes implemented in malaria endemic countries have successfully scaled up 
existing malaria interventions and ultimately led to a decrease in malaria cases worldwide  (WHO 
2012), along with increased funding and political commitment (Ravishankar et al. 2009; Mendis et al. 
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2009; World Malaria Report 2011; PMI 2012). Interventions such as distributing insecticide treated 
nets (ITNs) — 145 million in 2010 and 66 million in 2012 — resulted in almost 60% of households 
owning a net and 33% of the population sleeping under a bed net. Indoor residual spraying (IRS) 
protects 10-12% of the population (World Malaria Report 2012). In most Sub Saharan Africa (SSA) 
countries, fewer than 50% of the at-risk population is protected by ITNs or IRS.  Prompt diagnosis 
using rapid diagnosis tests (RDT) and efficient treatment with Artemisinin Combination Therapies 
(ACT) are efficient tools for reducing malaria. In 2009, 33 million RDTs were distributed, compared 
with 200,000 in 2005. In 2010, 229 million doses of ACT were procured worldwide, compared with 
2.1 million in 2003 (World Malaria Report 2010). An efficient and strategic mix of malaria 
interventions have contributed to decreasing cases by 50% or more (WHO 2012).  
1.2.3 Malaria Control Strategies in Tanzania 
Between 2000 and 2010, reported mortality among children under five in Tanzania fell from 148 per 
1000 live births in 1999 to 81 per 1000 live birth in 2010. In Ifakara, under five deaths were reduced 
from 25% in 2004 and 2005 to less than 5% in 2010 (World Malaria Report 2012; PMI 2012).  The 
decline was associated with increased external resources; between 2003 and 2010, about USD 450 
million were allocated to scale up malaria control programmes (World Malaria Report 2012; PMI 
2012). The data indicates that Tanzania has been able to reduce the malaria burden due to the high 
coverage achieved by malaria control strategies.  Some 18, 562 571 ITNs were distributed in the 
country between 2007 and 2010. Almost 63% of all households owned at least one ITN in 2010 
compared with 23% in 2004 - 2005. Nearly 64% of all children under five and 56% of all pregnant 
women used ITNs before the 2010 survey. IRS expanded to almost 94% in 18 districts from 2007 to 
2011. RDTs and ACTs were deployed to reach almost half of the population (World Malaria Report 
2012; PMI 2012). To ensure continued high coverage, policies and strategies are needed to guide the 
future implementation of new malaria interventions, including the malaria vaccine.   
1.3 The Need and Position for Policies and Strategies for Malaria 
In 2011, The World Health Organization’s Global Malaria Programme (WHO-GMP) established the 
Malaria Policy Advisory Committee (MPAC) to guide policy recommendations for malaria control and 
elimination In 2011 (Malaria Policy Advisory Committee 2012; World Malaria Report 2012). For the 
case of malaria vaccine RTS,S; the process of developing policy recommendations led to two 
departments, immunization Strategic Advisory Group of Experts (SAGE) and malaria (MPAC), jointly 
setting up a Joint Technical Expert Group (JTEG). The JTEG and MPAC will assess the evidence and 
MPAC and SAGE will review the report. If there is sufficient data to make a draft policy 
recommendation for malaria vaccines RTS, S, it will likely occur in 2015 (Mendis et al. 2009; Malaria 
Policy Advisory Committee 2012). Policy implications focus on the need for scientific evidence to 
  
7 
 
inform policy recommendations.  MPAC highlights the need for timely and high quality information 
to guide malaria control policies and to effectively communicate evidence to policy makers. MPAC 
also encourages the involvement of various stakeholders in order to ensure that policy 
recommendations reflect the needs and concerns of stakeholders (Malaria Policy Advisory 
Committee 2012). 
1.3.1 Tanzania National Malaria Advisory Committee’s Role in Policy Implementation 
Two separate ministries of health operate in the United Republic of Tanzania (URT), one each for the 
mainland and for Zanzibar. Each ministry has its own National Malaria Control Program (NMCP) and 
Malaria Strategy Plan. The mainland’s NMCP has established committees to coordinate national 
malaria control policies and priorities. The National Malaria Advisory Committee (NMAC) is the body 
that provides policy direction for malaria control on the mainland. The NMAC links the various NMCP 
committees to the SWAp structures of the Ministry of Health and Social Welfare (MOHSW). The 
NMAC provides technical advice on malaria control to the NMCP (United Republic of Tanzania 2006; 
PMI 2011). The committee meets annually to discuss and assess problems resulting from 
implementation of malaria intervention policies (Makundi et al. 2007). 
1.3.2 Malaria Vaccine Decision Making Framework (DMF) 
In 2006, WHO’s Africa Regional Office and PATH Malaria Vaccine Initiative (PATH MVI), in partnership 
with various multilateral and bilateral stakeholders, researchers, and several Ministries of Health, 
including Tanzania, developed a draft Decision Making Framework (DMF) to help identify evidence to 
support a policy decision to introduce the malaria vaccine within their national health systems.  The 
DMF for the malaria vaccine outlines the data required from different levels (global and national), in 
different thematic areas (disease burden, other malaria interventions, impact, financial, efficacy, 
safety, programmatic, socio cultural) and at different periods (pre licensure, licensure and post 
licensure of malaria vaccine) (Wells and Brooks 2011; Brooks and Ba-Nguz 2012).  The main objective 
for a DMF is to contribute to timely, evidence-based decisions about whether or not to introduce the 
malaria vaccine in a particular country or region. It has been noted that insufficient planning and lack 
of evidence-based information to inform the policy and decision making process is a reason for 
delays between development and availability of new interventions in low and mid income countries 
(Brooks and Ba-Nguz 2012). To overcome these challenges, the Tanzania Malaria Vaccine Secretariat 
(TMVS) was established to enable national authorities to obtain all necessary information 
surrounding the introduction of a new malaria vaccine in the health system. 
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1.3.3 Tanzania Malaria Vaccine Secretariat (TMVS) 
The Tanzania Malaria Vaccine Secretariat (TMVS) was established in 2009 to coordinate the 
implementation of the national malaria vaccine DMF.  TMVS generates information that will guide 
the policy process and aid national policy makers to identify critical data for deciding whether to 
introduce a new malaria vaccine. The following institutions are represented in TMVS:  Ministry of 
Health and Social Welfare (MOHSW) Mainland and Zanzibar, Immunization and Vaccine  
Development (IVD), National Malaria Control Programme (NMCP),  Tanzania Food and Drug 
Authority (TFDA),  National Institute for Medical Research (NIMR), Ifakara Health Institute (IHI), 
African Malaria Network Trust (AMANET), Association of Private Practitioners, WHO IVD and Malaria 
departments, UNICEF IVD and Malaria departments, Development Partners Group (Health), 
Commission for Sciences and Technology (COSTECH),  Muhimbili University of Health and Allied 
Sciences (MUHAS), and Tanzania NGOs Alliance Against Malaria (TANAM). The secretariat was 
endorsed by the Director of Preventive Services in the MOHSW.  The TMVS will be operational until a 
decision is made about introducing the malaria vaccine. The TMVS coordinates collaboration 
between researchers, IVD and NMCP and other stakeholders to collect needed information for a 
timely and well-informed decision and to ensure that processes are in place for policy-decisions on 
introducing a Malaria vaccine in the Tanzanian health systems (TDHS 2010; PATH MVI 2008).  
1.3.4 Malaria Vaccines: A New Tool for Malaria Control 
Malaria endemic countries are consolidating their gains to enter the pre-elimination stage of malaria. 
Research and development initiatives are on-going to develop other interventions against malaria, 
such as a malaria vaccine. In Tanzania, the Ifakara Health Institute (IHI) and National Institute for 
Medical Research (NIMR) have been at the centre of clinical trial efforts towards developing the RTS, 
S vaccine, with support from the PATH Malaria Vaccine Initiative (MVI), through the Bill & Melinda 
Gates Foundation and in collaboration with the pharmaceutical company GlaxoSmithKline (GSK). 
Malaria vaccine RTS, S clinical trials have completed phase III and RTS,S is on track for  registration. 
The malaria vaccine would complement existing interventions, such as ITNs, IRS and effective 
medicines.  At the end of the on-going clinical trials for malaria vaccines, policy makers need to be 
provided with scientific advice on whether to adopt the vaccine or not. In this regard, early planning 
is essential.  WHO has indicated that the malaria vaccine would be implemented in countries through 
Immunization, Vaccine and Biologicals (IVB) (Malaria Policy Advisory Committee 2012). 
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1.3.5 Immunization and Vaccine Development (IVD)  
Most developing countries have adopted the WHO’s guidelines for vaccinating children. According to 
those guidelines,  children  should receive the following vaccinations:  Bacillus Calmette Guerin 
(BCG), Oral Polio Vaccine (OPV), Diptheria Pertusis Tetanus - Hepatitis B virus Haemophilus influenza 
type b (DPT-HepB-Hib), Measles, TT, Rotarix, Pneumococcal Conjugate Vaccine (PCV13) (TDHS 2010; 
Tanzania EPI Report 2010). The Immunization Programme in Tanzania is implemented by the 
MOHSW through IVD, which started in 1975. IVD aims to protect children from Vaccine Preventable 
Diseases. This is expected to be attained through high and effective vaccination coverage for all 
antigens, using quality vaccines (TDHS 2010; Tanzania EPI Report 2010).  Therefore, there is a need to 
understand IVD programmatic feasibility, such as storage capacity, adequacy and skills of health 
personnel involved in immunization, surveillance system and guidelines for immunizations and 
feasibility considerations including scheduling and booster doses of malaria vaccine, in order to 
inform decision making for malaria vaccine introduction.   
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2. Goal, objectives and methods    
The study goal, objectives and methods are presented in this chapter. The objectives are rooted in 
the need to prepare the groundwork for formulating and implementing the forthcoming malaria 
vaccine, RTS,S. A first step is to ensure that evidence-based information informs the policy process 
and decision making.  There are a number of issues to be considered, such as the context in which 
the new vaccines are perceived (community perceptions), and the factors influencing different actors 
and the decision-making process in general. A framework to provide a comprehensive understanding 
of the policy process and steps involved along with recommendations and guidelines to advance the 
policy decision making process for the forthcoming malaria vaccine contributes to generating and 
sharing evidence-based information relevant to the needs of various stakeholders.   
2.1 Goal  
To analyse the decision making and policy development process for introducing new malaria 
interventions in Tanzania, in the absence of malaria vaccine use. 
2.2 Objectives 
Objective 1 
To describe and analyse the Tanzanian population’s awareness of and willingness to use malaria 
vaccines and to provide policymakers with evidence-based information about whether or not to 
adopt the forthcoming RTS,S malaria vaccine. 
Objective 2 
To describe and analyse comparatively the policy-making process for introducing new malaria 
interventions into Tanzania and to discuss it in relation to the situation in other RTS, S African 
countries.   
Objective 3 
To establish recommendations and guidelines for maximizing the effectiveness of the decision-
making and policy process surrounding the introduction of a malaria vaccine in Tanzania.  
2.3 Methods  
2.3.1 Brief outline of the methods used to achieve each of the objectives 
Objective 1  
A large cross-sectional study of 23 regions of Tanzania (mainland Tanzania and Zanzibar) used 
randomly sampling probability to assess awareness of and willingness to use a malaria vaccine 
among women aged 18 years or older with children less than 11 months old.   
Objective 2  
Document review to RTS,S African countries and in-depth interviews with 20 key informants’ were 
conducted at national level with government officials, bilateral and multilateral partners and other 
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stakeholders to assess malaria treatment policy changes in Tanzania and other RTS,S African 
countries. A comparative table and framework analysis was used as a practical guide to the steps of 
the decision making and policy process and validated in Tanzania and other RTS, S African countries.   
Objective 3 
The results obtained from Objectives 1 and 2 were synthesised and analysed to develop a practical 
guide (recommendations and guidelines) for malaria vaccine implementation. 
Conclusion  
This section provides a broad overview of the study methodology, including the study goal, study 
design and general methods used to achieve each study objective. Greater methodological detail is 
given in the following chapters. 
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3.1   Abstract  
Background: Clinical trials of the RTS,S malaria vaccine have completed Phase III and the vaccine is 
on track for registration. Before making decisions about implementation, it is essential to prepare the 
ground for introducing the vaccine by assessing willingness to use malaria vaccines. National decision 
makers need evidence-based information to decide about adopting the malaria vaccine in their 
respective countries. 
Methods: In November 2011, as part of a large cross-sectional study of 23 regions of Tanzania 
(mainland Tanzania and Zanzibar) was conducted during Tanzanian Integrated Measles Campaign 
(IMC) survey. In this study, the variables of interests were awareness of and willingness to use a 
malaria vaccine. The main outcome measure was willingness to use a malaria vaccine. Logistic 
regression was used to examine the influence of predictive factors.  
Results:  A representative sample of 5,502 (out of 6,210) women, aged 18 years or older and with 
children under 11 months old, was selected to participate, using random sampling probability. 
Awareness of the forthcoming malaria vaccine, 11.8% of participants in mainland Tanzania 
responded affirmatively, compared to 3.4% in Zanzibar. The difference was highly statistically 
significant (p-value<0.001) However, 94.5% of all respondents were willing to vaccinate their children 
against malaria, with a slight difference between mainland Tanzania (94.3%) and Zanzibar (96.8%). 
The difference was statistically significant (p-value=0.02). 
Conclusions: Although mothers were substantially had low awareness of the forthcoming availability 
of a malaria vaccine, their willingness to use the malaria vaccine was high. RTS,S will compliment 
other existing malaria interventions and it will be implemented through the Immunization, Vaccines 
and Biologicals (IVB) programme (formerly Expanded Programme on Immunization-EPI). The 
information generated from this study can aid policy makers in planning and setting priorities for 
introducing and implementing the malaria vaccine 
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3.2  Background  
Malaria still remains a significant public health problem in Sub-Saharan Africa, including Tanzania, 
accounting for 10% of the observed burden of disease (World Malaria Report 2013). Recently, 
technical innovations to control malaria have contributed to a decline in the malaria burden, but the 
disease remains a significant threat due to persistent enabling environments, poverty and fragile 
health systems (World Malaria Report 2013). Therefore, additional strategies are needed to ensure a 
combination of interventions that target the various phases of the malaria life cycle, including 
malaria vaccination (Graves and Gelband 2006). Vaccines have contributed significantly to reducing 
as well as to eliminating the burden of disease due to vaccine preventable infections (Orenstein and 
Hinman 1999; Batt, Fox-Rushby, and Castillo-Riquelme 2004; de Timóteo Mavimbe et al. 2006; 
Larson et al. 2011; Bloom 2011; Murele et al. 2014; Burchett et al. 2012).  
There are on-going efforts to deliver malaria vaccines as a means to achieving elimination. Malaria 
vaccine RTS, S is the most advanced candidate to undergo large scale Phase III evaluation in Africa. It 
has been tested in 11 African sites with varying degrees of malaria transmission. The study sites 
included: Nanoro in Burkina Faso; Kintampo and Agogo in Ghana; Lambarene in Gabon; Manhica in 
Mozambique; Lilongwe in Malawi; Kilifi, Siaya and Kombewa in Kenya; and Bagamoyo and Korogwe 
in Tanzania (RTS,S Clinical Trials Partnership 2014). The availability of RTS,S will contribute to a multi-
intervention approach to controlling malaria that currently uses LLITNs,  ITNs, IRS, and other means 
of disease reduction and effective drug treatment.  Phase II and III clinical trials of RTS,S showed that 
the vaccine reduced the episodes of malaria among young children and infants in malaria endemic 
areas by half (Abdulla et al. 2008; Ojakaa et al. 2011; “A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine 
in African Infants” 2012; RTS,S Clinical Trials Partnership 2014). Upon completion of the clinical trials, 
policy makers will need to make evidence-based decision on the best ways to engage communities to 
facilitate introduction of malaria vaccine in the national health systems using Tanzania as a case 
study. 
Studies on vaccine adherence interventions and acceptance of vaccines recommended use of 
strategies that will enhance positive community knowledge and perceptions on vaccine effectiveness 
(Nuño, Chowell, and Gumel 2007; Vardavas, Breban, and Blower 2007). Effectiveness of vaccines rely 
on both clinical efficacy and on a community’s perceptual factors (Murele et al. 2014). During vaccine 
promotion lack of community support  due to poor knowledge and  perceptions made community 
delay the uptake while others reject vaccines (Febir et al. 2013). Similar contexts existed when Polio 
vaccination programme was delayed in northern Nigeria (Wonodi et al. 2012; Yahya 2007). Another 
similar experiences was the community refection of deworming programme in Ghana (Dodoo et al. 
2007; Febir et al. 2013).  
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Whereas Tanzania shares similar social cultural and economic contexts to those countries mentioned 
above there is a high likelihood that new of even current vaccines can be similarly rejected and thus 
undermining efforts to adopt new technologies to address the high burden of disease. Therefore  it is 
crucial that community awareness of  and willingness to use the malaria vaccine as well as 
community perceptions of its likely impact are well understood and used to highlight any 
community-based issues that need to be considered during policy deliberation and intervention 
planning (Brooks and Ba-Nguz 2012). The policy recommendations for introducing malaria vaccine 
RTS,S would be implemented in countries through the World Health Organization’s IVB  (formerly 
EPI) (D’Souza and Newman 2012). Based on this, the case study was initiated with the following 
objective: To describe and analyse the Tanzanian population’s willingness to use malaria vaccines and 
to provide policymakers with evidence-based information on the best strategies to manage the 
introduction of new vaccine and in this case malaria vaccine. 
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3.3 Methods 
Study design and setting  
In November 2011, as part of a large cross-sectional study of 23 regions of Tanzania (mainland 
Tanzania and Zanzibar) was conducted during Tanzanian IMC survey. The study was designed to 
assess awareness of the forthcoming malaria vaccine and willingness to use malaria vaccine among 
women aged 18 years or older with children less than 11 months old.     
Study sample size and sampling procedure 
It was anticipated that the overall immunization coverage in the surveyed regions was estimated to 
be 85% (the desired precision is ±5% with 95% confidence). Thirty clusters were sampled 
(Immunization and Biologicals 2005), and 9 women with children 0-11 months old per cluster were 
identified. A total of 6,210 women with children 0 – 11 months old were recruited. For the purpose 
of this analysis, only 5,502 women met the eligibility criteria and were included in the final analysis 
(n=5502). 
The sampling procedure was based on 30-by-9 method and simple random sampling applied. The 30-
by-9 method was a two-stage cluster sample. In the first stage, 30 clusters (corresponding to 
Enumeration Areas - EAs) were sampled by a Probability Proportion to Size (PPS) strategy using the 
CSurvey software. In the second stage of sampling, 9 eligible women with children 0-11 months old 
were selected within each EA.  
Not all of the first 9 households visited had an eligible child; therefore, more than 9 households may 
have been visited. Similarly, fewer than 9 households may have been selected if there was more than 
one eligible child per household. A sample of 30 enumeration clusters (villages) per region was 
surveyed; the minimum sample size was 270 mothers in each region. In each region 30 clusters were 
visited and in each cluster, nine mothers with a child aged 0–11 months old were randomly selected 
and visited. The following steps were followed; 
1. Within the regions, 30 EAs were selected using the PPS strategy. 
2. In each EA, 9  eligible children were selected from households as follows: 
a. Go to the “centre” of the EA. 
b. Throw a pen to choose a random direction. 
c. Walk in that direction to identify the first household.  
d. Visit the first selected household and start to recruit the eligible children. 
e. After the first household visited, data collector moved to the “next household”, 
which was defined as the one whose front door was the closest to the just one 
visited. 
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f. This process was continued until all 9 eligible children were found/ reached. 
Primary outcome and explanatory variables 
The primary outcome variable was willingness to use a malaria vaccine; mothers were asked if they 
would like their children to receive malaria vaccine. The following explanatory variables of 
willingness to use a malaria vaccine were investigated: 1) Awareness of the forthcoming malaria 
vaccine; mothers were asked if they ever heard about malaria vaccine. 2) Knowledge of the health 
benefits of vaccinating under-five children, mothers were assessed if they know malaria vaccine can 
prevent children from getting malaria, reduced disease infection and death or enhance good health. 
3) Mothers to accept the mode of administering the malaria vaccine (require 2-3 jabs to receive full 
benefit). 4)  Mothers to agree proposed schedule of given malaria vaccine at the same health facility 
and at the same time as other childhood vaccines. Other explanatory variables were ITNs ownership, 
EPI and measles vaccination.  
Data collection  
Data was collected using structured questionnaires (Appendix 4) that assessed mothers of eligible 
children on their awareness of the forthcoming malaria vaccine, their willingness to use a malaria 
vaccine, their knowledge of the health benefits of vaccinating children under-five, their acceptance of 
the mode of administering the malaria vaccine and its proposed schedule. The study was limited due 
to lack of data collection on demographic data.  Data on ITNs ownership, EPI and measles coverage 
generated from the Tanzania Demographic and Health Survey (TDHS) 2010. 
Data management and analysis 
Data were double entered from data collection forms into a computer data file using Data 
Management System for Clinical Trials Software (DMSys) (Sigma soft International, Cincinnati, USA) 
(http://www.sigmasoftintl.com/products.asp). Data were reviewed after the initial data entry to 
check for out-of-range responses, missing values, or inconsistent skip patterns; the original data 
collection sheets were reviewed to resolve any discrepancies or problems. 
The data were analysed using STATA 11 standard edition software (StataCorp, Texas, USA). The data 
were summarized using frequency tables and cross tabulation. Cross tabulation was done to assess 
the association between knowledge of the benefits of under-five vaccination and awareness of the 
forthcoming malaria vaccine; and between knowledge of the benefits of under-five vaccination and 
willingness to use a malaria vaccine. Categorical data was reported with numbers and percentage 
and their associated p-values. Cross tabulation and Chi square was used to test association between 
variables in a two by two table. Fisher’s exact test was used to compare proportions in two by two 
tables where expected value in a cell was less than five. Univariate logistic regression was used to 
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determine the magnitude of association for each exposure variable and outcome variable. Variables 
that showed association at a 0.25 significance level in univariate analysis were considered as 
candidates for the multivariate analysis. Multiple logistic regressions were used to determine the 
association between willingness and the primary exposure variable, while controlling for possible 
confounders. P-values of less than or equal to 0.05 were considered significant. 
Ethical approval 
The study was part of the Tanzanian IMC survey in November 2011 and received ethical approval 
from the Institutional Review Boards of Ifakara Health Institute. We obtained written informed 
consent from all participants prior to the start of the interviews. 
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3.4 Results 
When asked about awareness of the forthcoming malaria vaccine, 11.8% of participants in mainland 
Tanzania responded affirmatively, compared to 3.4% in Zanzibar (Appendix 2). The difference was 
highly statistically significant (p-value<0.001) (Table 1). However, 94.5% of respondents were willing 
to take their children to get malaria vaccination, with a slight difference between mainland Tanzania 
(94.3%) and Zanzibar (96.8%) (Appendix 2). The difference was statistically significant (p-value=0.02) 
(Table 1). 
Most (88.4%) of the respondents reported knowing the benefits of vaccinating children under-five, 
with 88.5% in mainland Tanzania and 87.9% in Zanzibar (Appendix 3). The difference was not 
statistically significant (p-value =0.7) (Table 1). The majority (81.3%) of respondents reported 
accepting the mode of administering the malaria vaccine (2-3 jabs), with a high proportion (82.6%) of 
acceptability among mainland Tanzanians than in Zanzibar (68.8%) (Appendix 3); the difference was 
statistically significant (p-value<0.001) (Table 1). Most (86.7%) respondents would send their children 
for malaria vaccine according to the proposed schedule, with 86.7% of respondents in mainland 
Tanzania and 87.1% of respondents in Zanzibar (Appendix 3); the difference was not statistically 
significant (p-value=0.8) (Table 1). 
The proportion of respondents with knowledge of malaria prevention, mainly ITN ownership, was 
71.7% overall, and slightly higher in Zanzibar (73.1 %) as compared to mainland Tanzania (71.5 %); 
the difference was not significant (p-value=0.4, Table 1).  Respondents whose children received EPI 
vaccines were 84 % overall and significantly higher (90.8%) in Zanzibar compared to mainland 
Tanzania (83.8 %). However, respondents whose children received EPI vaccines were statistically 
significant (p-value < 0.001, Table 1). Overall, 72.2 % of respondents whose children received measles 
vaccines, respondents whose children received measles vaccines were similar between Zanzibar 
(72.3%) and mainland Tanzania (72.2%). The difference was not statistically significant (p-value = 0.9, 
Table 1). 
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Table 1.  Perceived indicators of RTS,S vaccine delivery and public interventions coverage in  
Zanzibar and Mainland, Tanzania  
Perceived indicator  Zanzibar (%) Mainland (%) p-value 
Willingness 96.8   94.3 0.02 
Awareness 3.4 11.8  < 0.001 
Benefit 87.9 88.5 0.7 
Delivery mode 68.8 82.6 < 0.001 
Proposed schedule 87.1 86.7 0.8 
ITN ownership 73.1 71.5 0.4 
Received EPI vaccines 90.8 83.8 <0.001 
Received measles vaccines 72.3 72.2 0.9 
 
Factors associated with willingness to use malaria vaccine 
Willingness to use malaria vaccine was not associated with awareness of the forthcoming malaria 
vaccine. However, knowledge of benefits of vaccinating under-five children, acceptance of the mode 
of administering the malaria vaccine and proposed schedule were associated with willingness to use 
malaria vaccine.  In multivariable analysis, mothers who reported to know the benefit of vaccinating 
under-five children were more likely to use malaria vaccine than those who didn’t know (OR: 3.5; 
95% CI: 2.57–4.75; p < 0.001). Mothers who reported to accept the mode of administering (2-3 jabs) 
malaria vaccine were more likely willing to use malaria vaccine than those who did not accept (OR: 
16.78; 95% CI: 11.47–24.54; p < 0.001). Mothers who reported to agree with proposed schedule of 
the forthcoming vaccine were more likely willing to use malaria vaccine than those who did not agree 
(OR: 14.68; 95% CI: 10.51–20.51; p < 0.001) (Table 2). 
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Table 2. Factors affecting willingness to use malaria vaccine (N = 5502) 
Assessed indicators 
Univariate analysis Multivariate analysis 
OR (95% CI) p-value OR (95% CI) p-value 
Awareness  
No 
Yes 
 
1 0.2 
 
1 0.7 
1.3 (0.8 -1.9) 0.9 (0.5 - 1.5) 
Benefits of vaccination  
No 
Yes 
 
1 
< 0.001 
 
1 
< 0.001 
3.3(2.6 - 4.1) 3.5 (2.6 - 4.8) 
Mode of administering (2-3 injections) 
No 
Yes 
 
1 < 0.001 
 
1 < 0.001 
38.8 (27.5 - 54.8) 16.8 (11.5 - 24.5) 
Proposed Schedule  
No 
Yes 
 
1 < 0.001 
 
1 < 0.001 
39.6 (29.4 - 53.4) 14.7 (10.5 - 20.5) 
 
  
22 
 
 
3.5 Discussion 
The study was conducted to test awareness of and willingness to use a malaria vaccine which has not 
yet been propagated in a sample of women older than 18 years of age, with children less than 11 
months, in 23 regions in Tanzania (21 regions in mainland Tanzania and 2 regions in Zanzibar -Unguja 
and Pemba). Information from this study can be used prepare ground for policy decisions and for 
intervention planning. 
Understanding community perceptions can help to identify issues to guide policy decisions for 
introducing the malaria vaccine. These findings are similar to studies documenting the need for early 
planning for new interventions, essential for policy decision making; relevant information can speed 
up the efforts to facilitate its implementation (Brooks and Ba-Nguz 2012). Understanding community 
perceptions of a malaria vaccine also helps to inform country programme managers responsible for 
NMCP and IVD priority setting and planning. 
Our results on the low  (11%) level of awareness of the forthcoming malaria vaccine and high (94.5%) 
willingness to use a malaria vaccine were similar to those found by Colon-Lopez and others for HPV 
vaccination in Puerto Rico (Colón-López et al. 2012), which also indicated low (28.3%) level of 
awareness of and high (76.9%) willingness to use HPV vaccines. Both findings come from settings 
where none of the study participants had been vaccinated. This finding suggests that creating 
awareness of the malaria vaccine would be effective; currently understanding among respondents is 
low because the malaria vaccine is new and most people had not yet learned about it. Informing 
women about the malaria vaccine would likely increase women’s interest in their willingness to use a 
malaria vaccine. Creating awareness could reveal policy-related issues that, once addressed, could 
support decisions for malaria interventions (Burchett et al. 2012) and child vaccinations (Dempsey et 
al. 2006). 
Low awareness of the forthcoming malaria vaccine was compared to both willingness to use a 
malaria vaccine and knowledge of the benefits of vaccinating children under-five. This finding is 
consistent with others’ findings in Kenya and Ghana that showed wide spread knowledge of 
childhood vaccinations (Ojakaa et al. 2011); in Ghana, over  90% of respondents understood that the 
malaria vaccine had benefits related to child vaccinations (Febir et al. 2013; Dempsey et al. 2006; 
Ojakaa et al. 2011; Bingham et al. 2012). Contrary to the study conducted when malaria vaccine 
efficacy results were not yet available, the level of willingness to use a malaria vaccine differed when 
respondents considered low efficacy results compared to other childhood vaccines (Febir et al. 2013; 
Olotu et al. 2013). Knowledge of existing routine immunization schedules and benefits increased the 
level of willingness to use a malaria vaccine. The structure of the immunization programme in 
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Tanzania is widely spread and accessible to the majority of Tanzanian women.  As the malaria vaccine 
is expected to be delivered through the immunization programme, women would expect the 
vaccine’s benefits to be in line with those of other routine vaccinations. Therefore, informing women 
about the benefits of vaccinating children under-five is likely to increase women’s interest in the 
forthcoming malaria vaccine and their willingness to use it. 
High acceptance of the mode of administering a malaria vaccine (2-3 jabs) according to the proposed 
schedule was similar to findings by Febir and others who showed that respondents were willing to 
receive vaccines in the form of injections, as most understood that  “vaccines are injections given to 
children in their childhood to prevent occurrences of diseases” (Febir et al. 2013). Contrary to Parvez 
and others, immunization injections were perceived to be painful procedures (Parvez et al. 2010). 
The injection method becomes a challenge when increasing numbers of injections as women become 
less willing to take their children for malaria vaccination. After the end of routine vaccination, 
parents might not take their children for additional vaccinations for a variety of reasons, including 
mothers’ competing priorities.   Immunization clinics at health facilities and in informal areas (mobile 
clinics) can be good avenues for informing women about the malaria vaccine and for scheduling 
children for vaccination. 
The strengths of the study include: larger sample size, representative sampling and combining data 
on awareness of the forthcoming malaria vaccine, willingness to use a malaria vaccine, knowledge of 
the benefits of vaccinating children under five, acceptability of the mode of administering the vaccine 
according to the proposed schedule, ITN ownership, and knowledge of EPI and measles vaccinations. 
The study had a number of limitations, including the difficulty in determining acceptance of a malaria 
vaccine that is not yet available. It is likely that there are other reasons not covered by this study that 
account for some women’s lack of awareness of a forthcoming malaria vaccine and their 
unwillingness to use a malaria vaccine. For example, the vaccine may be accepted by the parents but 
still they do not take their children for vaccination due to distance, competing maternal priorities and 
lack of time. 
Conclusions and recommendations 
Although mothers were highly unaware of a forthcoming malaria vaccine, they were very willing to 
use a malaria vaccine. Identifying regions with both low awareness of a forthcoming malaria vaccine 
and low willingness to use malaria vaccines would allow appropriate advocacy strategies to be 
planned and communication strategies to be developed before introducing the malaria vaccine in 
Tanzania. Malaria vaccine RTS,S will complement existing malaria interventions and be implemented 
through the IVD. The information generated by this study can aid policy makers as they plan and set 
priorities for introducing and implementing the malaria vaccine 
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It is recommended that awareness of a potential malaria vaccine be created in the entire Tanzanian 
community, specifically among mothers who should be informed of both the benefits related to child 
vaccination and of the malaria vaccine. This could be accomplished by disseminating information to 
enhance maternal readiness for adopting malaria vaccination. 
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4.1 Abstract 
Background  
Traditionally, it has taken decades to introduce new interventions in low-income countries. Several 
factors account for these delays, one of which is the absence of a framework to facilitate 
comprehensive understanding of policy process to inform policy makers and stimulate the decision-
making process.  In the case of the proposed introduction of malaria vaccines in Africa, a specific 
framework for decision making will speed up the administrative process and shorten the time until 
the vaccine is made available to the target population.  
Methods: Document review and qualitative research tools were used as a basis for conducting key 
informant interviews, developing the Policy Analysis Framework and analysing stakeholders. 20 key 
informants at national level were assessed in Tanzania between July and August 2012. Interviews 
were conducted with government officials, bilateral and multilateral partners and other 
stakeholders. Semi-qualitative analysis applied to RTS,S African countries to assess malaria treatment 
policy changes and to draw lessons for malaria vaccine adoption. 
Results: The framework was developed and applied to RTS, S African countries with regard to its 
readiness for adoption of the forthcoming malaria vaccine. The rating implies that Tanzania (12), very 
good), Burkina Faso (10), Malawi, (9), Kenya and Gabon (8) good) are prepared.  Ghana scores poorly 
on policy promoting factors (5), little) and documented information on barriers. Mozambique also 
scores low on promoting factors and documented barriers ((1) weak). 
Conclusion: The framework is a comprehensive tool that enables one to unpack the content and 
contextual factors surrounding the decision to introduce a potential malaria vaccine in African RTS, S 
countries. Furthermore, the framework provides an effective way to deepen our knowledge of the 
policy process and to inform the policy decision-making process for new malaria interventions, 
generally, and for the forthcoming malaria vaccine, specifically. It is an applicable and appropriate 
tool for African RTS,S countries and other low resourced settings. Lastly, the framework facilitates 
the synthesis of information in a coherent way, enabling a clearer understanding of the policy 
process, thereby speeding up the policy decision-making process and shortening the time until the 
forthcoming malaria vaccine becomes available. While we find the framework useful and applicable, 
we still feel that further validation is required. 
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4.2 Background 
Introducing new technologies for diagnosis and treatment is often expensive and demands specific 
biological, medical and technical capabilities to use them  (van Balen and Gerrits 2001; Bahamondes 
and Makuch 2014). They also require a certain level of infrastructure, effective  health systems for 
example, to deliver high quality materials and services that make new technologies accessible and 
affordable (van Balen and Gerrits 2001; Frost and Reich 2009; Bahamondes and Makuch 2014). 
Creating access to new technologies requires understanding of the users’ preferences, concerns and 
the context in which the new technologies are perceived. Successful delivery of new technologies 
depends on health system performance (van Balen and Gerrits 2001). The case of Norplant in 
Indonesia and the United States demonstrated how failure to consider the current state of a health 
system can hinder access. A new contraceptive implant technology required both insertion and 
removal by a trained provider. The providers were trained on how to insert the implants but they 
were not provided with removal skills, resulting in difficulties with implant removals (Frost and Reich 
2009). Health systems’ strengthening can also ensure that new products are designed to improve 
people’s health in the context of their needs and preferences. Thus, people’s needs have a role to 
play in access to new technology and, consequently, the effect and overall benefits of new 
technology.  Availability of new technologies and interventions require policy makers and others to 
make decisions about whether or not to adopt them.  
Even when a decision is made to adopt and implement a new health intervention in low and middle 
income countries (LMICs), it often takes years or decades before the benefits of the new 
interventions are realised (Kane and Brooks 2002; Bosman and Mendis 2007; Frost and Reich 2009; 
Levine, Knoll, et al. 2010; Brooks and Ba-Nguz 2012). This is due to delays in availability of new drugs, 
for example, due to cultural differences in perceptions of medical needs and costs (Berndt and 
Cockburn 2014). Delays in new vaccine adoption (Clemens and Jodar 2004; DeRoeck, Jodar, and 
Clemens 2007; Jacqueline Sherris et al. 2006) are commonly due to financial  constraints, political 
obstacles (Clemens and Jodar 2004) and competing health priorities (DeRoeck, Jodar, and Clemens 
2007), as well as absence of national disease burden data (Clemens and Jodar 2004), absence of 
vaccine efficacy data (Clemens and Jodar 2004; J. Sherris et al. 2005) and lack of sustainable supply 
mechanisms for the new vaccine (Mahoney 2004). As new interventions become available, it creates 
the need for greater understanding of the policy making process as it applies to technology adoption 
and implementation (DeRoeck 2004; Gericke et al. 2005; Bryson et al. 2010; Gessner et al. 2010; 
Grundy 2010; Levine, Hajjeh, et al. 2010; Victora 2010; Brooks and Ba-Nguz 2012; DeRoeck et al. 
2005).  Understanding  evidence-based information helps in planning, priority setting and choosing 
from among the available alternatives (Ashford et al. 2006; Moree and Ewart 2004). Lack of 
understanding could also slow down the policy decision making process as it relates to introducing 
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new interventions (Ashford et al. 2006; Moree and Ewart 2004), as was the case with for both 
Haemophilus Influenzae type b (Hib) conjugate vaccine implementation (Hajjeh et al. 2010; Mitchell 
et al. 2005) and malaria treatment policy change implementation in Tanzania (Williams, Durrheim, 
and Shretta 2004; Mulligan et al. 2006; Amin et al. 2007; Bosman and Mendis 2007).  Njau and others 
(2008) studied the influence of stakeholders in the decision to deliver ITNs. The authors critically 
analysed the stakeholders’ interactions with one another and how they were influenced by the 
contextual factors (Njau et al. 2009). Elements of framework such as actors and context can facilitate 
understanding of evidence based information needed to make decisions. 
Frameworks have been useful for identifying relationships among the elements that guide and 
inform health policy processes (Gill Walt et al. 2008). There are few frameworks used for policy 
analysis and the few that are available do not focus on specific policies to test the theory’s 
application (Gilson and Raphaely 2008). Most frameworks available lack information which could be 
validated in the field (Wenger et al. 1999; Munira and Fritzen 2007; Piso and Wild 2009; Burchett et 
al. 2012). Various models and frameworks describe the policy process and though they are not 
mutually exclusive, several make specific contributions on which this study is built. These include the 
Policy Analysis Framework (G. Walt and Gilson 1994), the Kingdon model (Kingdon and Thurber 
1984), Advocacy coalition’ framework (Sabatier and Jenkins-Smith 1999), Street-level Bureaucrat’s 
model (Lipsky 2010) and Reichs’ political analysis (Reich 1995). Given the focus of the present study; 
two frameworks were chosen because of how they complement each other. Policy Analysis 
Framework (G. Walt and Gilson 1994) highlights ways of understanding policy processes through 
elements such as policy content, context, actors and processes involved in making and implementing 
policy (G. Walt and Gilson 1994). The Kingdon model of agenda setting (Kingdon and Thurber 1984) 
helps to explain how certain issues get onto the government policy agenda and suggests three 
related processes — the problem stream, the politics stream and the policies streams — that when 
brought together, create a window of opportunity and increase the chance of policy adoption. 
Advocacy coalition (Sabatier and Jenkins-Smith 1999) actors in policy communities form advocacy 
alliances that compete to influence specific policy objectives. Street-level Bureaucrats model 
examines what happens when policy is translated into practice; that is, policy implementation (Lipsky 
2010). Reich’s (Reich 1995) work on political mapping helps to explain why certain policies do not 
succeed and could help to develop strategies to address challenges for future policy implementation 
(Reich 1995). The above mentioned models and frameworks of policy making are likely to be more or 
less relevant depending on the specific circumstances and policy processes surrounding adoption of 
new technologies, like the malaria vaccine RTS,S.  
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In this study, we adapted a framework based on Policy Analysis Framework concepts to inform the 
policy making process for introducing the forthcoming malaria vaccine, RTS,S, in Tanzania. The 
framework analyses factors influencing the policy making process, such as content, context, actors 
and processes in order to establish a mechanism that will facilitate timely management of the 
stakeholders, thereby ensuring timely rollout of the vaccine. Specifically, the framework generates 
information on the positions, influences and preferences associated with the rollout, which 
ultimately leads to better and more efficient management of the stakeholders. By applying the 
proposed frameworks to existing policy processes for malaria interventions and vaccines in Tanzania, 
we are able to distil lessons learnt that will also serve to guide the forthcoming malaria vaccine policy 
formulation and implementation.  
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4.3 Methodology 
Adapting Policy Analysis Framework 
The malaria intervention specific framework was analysed based on identified policy analysis 
approaches and existing general frameworks for studying policy processes (G. Walt and Gilson 1994). 
It draws heavily upon Policy Analysis Framework (G. Walt and Gilson 1994) focus on (context, and 
content, context, actors and process). But also incorporates elements from the kingdon model as 
listed and described.  The overall approach guides how elements influence the policy process and 
how issues get on the policy agenda (Kingdon and Thurber 1984) and the process through which 
policies are developed, formulated and implemented (G. Walt and Gilson 1994).   
The framework guiding the analysis is presented in Table 3 and Figure 3. Table 3 presents the four 
elements of the framework (content, context, actors and process). Figure 3 describes the different 
stages of the policy process in Tanzania and describes how content, context, actors and process are 
determined.  The analysis is presented in sections of this paper.    
Study population 
To better understand how various stakeholders engage in the policy making process for new malaria 
interventions and vaccines in Tanzania, qualitative methods were used, namely interviews with key 
informants.  A sample of 20 key informants at the national level was assessed between July and 
August 2012. Participant categories included:  international donors and public health stakeholders 
The US Agency for International Development (USAID), Presidents Malaria Initiative (PMI), World 
Health Organization (WHO), The United Nations Children Fund (UNICEF), Centers for Disease Control 
and Prevention (CDC); national and political institutions (Legislature, Members of Parliament); public 
health officials MOHSW; programme managers NMCP, IVD; regulatory authorities: TFDA; Ministry of 
Finance and Economic Affairs (MOFEA) and professional organisations, academia and research 
institutions: NIMR, IHI, AMANET & COSTECH. Key informants were selected based on their 
knowledge and involvement in the process of changing malaria treatment policy and adopting new 
vaccines in Tanzania.  Interviews were open ended, with questions that aimed to analyse the existing 
policy process for new malaria interventions and vaccines in Tanzania and to draw out lessons 
learned that could be applied to the forthcoming malaria vaccine policy adoption and 
implementation process. 
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Data collection  
The face-to-face semi-structured interviews began by soliciting verbal informed consent and 
permission to record the interviews. Interviews lasted between 40 — 60 minutes, depending on the 
level of detail offered by informants. Information gathered from the key informant interviews was 
used to map and analyse stakeholders in terms of interest and perceptions, capacity and motivation 
to adopt the policy and to determine possible actions for engaging stakeholders. Document review 
was conducted to RTS,S African countries 
Data analysis  
Interview notes were transcribed with the aid of recordings when available and uploaded and 
imported into MAXQDA 11 software for coding based on the themes derived from the interviews 
related to content, context, process and actors involved in the policy process.  Interviews were 
analysed thematically to understand the experiences of different stakeholders and to describe policy 
change processes.  
Document review to African countries where malaria vaccine RTS,S clinical trials were conducted to 
assess malaria treatment policy changes and to draw lessons for malaria vaccine adoption. Document 
review and qualitative research tools were used as a basis for conducting key informant interviews, 
developing the Policy Analysis Framework and analysing stakeholders. Policy Analysis  Framework 
facilitated analysis of the steps of content, the actors involved in decision making, contextual factors 
influencing the policy and the process of how policy was initiated, formulated and implemented (G. 
Walt and Gilson 1994). Stakeholders analysis helped to specifically identify individuals and groups, 
assess their power, resources, policy positions and their perceptions of the problem (Roberts et al. 
2008). Figure 2 outlined the stakeholder analysis.   The Policy Analysis Framework and concepts from 
the Kingdon model  (Kingdon and Thurber 1984),  were used to illustrate and interpret results.  
The study protocol, interview guide and consent for this study were reviewed and approved by the 
Institutional Review Board at the Ifakara Health Institute (IHI).  
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4.4 Results 
Findings are presented according to the concepts  drawn from Policy Analysis Framework (G. Walt 
and Gilson 1994): content (steps of content), context, actors and process (procedures) 
 
Figure 1. Policy Analysis Framework  
Steps of content in decision making 
In Tanzania, the process of making policy decisions for the introduction of malaria interventions 
involves several steps. Interview participants highlighted the steps of content as follows: i) reviewing 
the available evidence from different studies with consistent results and epidemiological data; ii) 
considering the availability of alternative interventions to replace the failing  intervention, including 
the cost of the new intervention; iii) forming  a task force or technical groups composed of doctors 
and bilateral and multilateral partners to get additional scientific inputs and correctly package the 
evidence in  language that can be easily understood by policy makers; iv) getting feedback from the 
National Malaria Advisory Committee (NMAC), a technical body with the mandate to review 
technical evidence before it is made available to policy makers at the next level; v) presenting 
scientific evidence to the NMCP Manager to convince him of the need for the new intervention 
(NMCP is the secretariat to the NMAC).  The NMCP secretariat prepares a brief summary, which, 
together with the recommendations from the NMAC, are presented to the Director of preventive 
services and to the Chief Medical Officer (CMO) of the MOHSW;  vi) the Director of Preventive 
Services and the CMO present the findings to the MOHSW Senior Management team to get their 
buy-in, endorsement and approval. Normally this meeting would be held in the presence of the 
NMCP secretariat. The MOHSW Senior Management team comprises all Directorates (the Permanent 
Secretary, Director of Preventive services, Director of Curative Services, CMO, Director of Policy and 
Planning, Director of Human Resources and Director of Quality Assurance). 
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Interview participants also identified the steps in making policy decisions for the adoption of new 
vaccines in Tanzania: i) reviewing the available evidence on the disease burden and other 
epidemiological data pertaining to the vaccine (efficacy, safety and  WHO–prequalification);  ii) 
considering the availability of the intervention; iii) developing a concept paper or a proposal based on 
the latest epidemiological data; iii) consulting experts, researchers, health institutions and  
development partners in order to get additional scientific inputs for developing the proposal and 
presenting the evidence and epidemiological data to the Malaria Steering Committee (MSC), which 
replaces the NMAC in this case; iv) presenting the MSC’s recommendations (via the NMCP 
secretariat) to the MOHSW’s Senior Management team to get buy-in, endorsement and approval of 
the proposal; v) presenting the proposal to the Inter-agency Coordinating Committee (ICC) of the 
MOHSW’s IVD unit so that the evidence is reviewed, and the cost analysis is discussed.  The ICC can 
recommend that the proposal be submitted to GAVI to apply for funding to support the vaccine’s roll 
out; vi) developing a comprehensive protocol for application for GAVI funds to introduce a new 
vaccine, including a detailed implementation plan, cost per annum (cMYP) and mechanisms for 
scaling up, among other details.  
In Tanzania, the decision-making process for adopting malaria interventions and new vaccines in 
general takes years, involving several steps: meetings and presentations of scientific data from 
different studies with consistent results, packaging and disseminating evidence and getting approval 
for use by the MOHSW. Other steps include considering the availability of an intervention backed by 
scientific proof and assessed for efficacy and side effects; a task force packages and summarises 
scientific results, and is followed by stakeholder meetings, consensus building with the MOHSW 
management team for approval and adoption. 
Context 
The analysis of the context in which malaria policy decisions are made yielded various themes. 
Themes were broadly categorized into one of two major areas, promoting and barriers factors. 
Promoting factors 
According to interview participants, the major factors influencing the policy process for both malaria 
interventions and vaccines include:  
Epidemiological and intervention characteristics  
WHO recommends that policy decisions for introducing new interventions be based on 
established evidence of the epidemiology and burden of disease and on the safety, 
effectiveness and efficacy of the specific intervention to prevent the target disease.  
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The interventions should be of high quality but the question of how MOHSW can ensure 
quality assurance for new interventions remains open. “We need to set criteria for quality 
assurance, which we don’t have yet; the criteria to accept or not to accept the new 
interventions, which we do not have yet. It is an important observation you have noted”. 
(“MOHSW stakeholder”). 
Country experiences of malaria treatment policy change 
Mapping the country and looking at decisions adopted in neighbouring countries with similar 
settings (as Tanzania) such as Kenya, Botswana, and Malawi, can influence policy decision 
outcomes. In those countries, SP has replaced CQ as the first line drug and had they have 
already revised their national drug policy guidelines, accordingly (“NMCP stakeholder”).  
Presentation and dissemination of evidence   
Technical groups translate the evidence in a manner that is digestible and understandable to 
policy makers. The groups include the Medical Association of Doctors, bilateral and multilateral 
partners, and scientific bodies. There are lessons to be learned from past experiences. A 
scientific package was developed at the time that treatment policy changed from SP to ACT. 
The package included operation and orientation knowledge, an analysis of the costs and cost 
effectiveness of the new intervention and scientific proof that validated the intervention 
locally, in the field.  When policy makers are well informed, they will get involved. The 
knowledge that the policy makers accumulate is important for adoption and approval 
decisions.  
“You have to simplify the language and hit the message about replacement of the 
intervention” (“Bilateral & Multilateral partners stakeholders”).  
“A package of the information reflects what you need to bring as a point of reference. The 
Prime Minister’s Office Local Government and Regional Administration (PMOLRAG) hire and 
fire employees, therefore packaging information brings those employees on board and gives 
them a policy level of understanding” (“Bilateral & Multilateral partners stakeholders”).  
Coordination and harmonization of the process 
Planning and harmonizing the policy process is done in collaboration with donors and other 
international stakeholders, from the conception stage to the final use of the findings. The 
process gives the opportunity from the outset to mobilize donor funding and to demonstrate 
to the donors and other partners the operational and other costs related to the policy 
adoption and implementation and to show that the policy is cost effective. When donors and 
partners are taken on board at the early stages of discussing the policy change, it gives an 
opportunity to strategies and leverage financial and technical support towards the aim, 
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thereby increasing the chance that the policy decision in question will be adopted (“Bilateral & 
Multilateral partners stakeholders”).  
Use of international scientific evidence  
The use of international scientific evidence adapted to the local context is important for 
informing related policy decisions. Availability of an international person introduces another 
perspective and helps to clarify scientifically proven evidence, thereby increasing the chances 
that a policy decision and intervention will be adopted (“Bilateral & Multilateral partners 
stakeholders”). 
Of all the contextual factors promoting policy adoption, as identified by interviewees, the ones that 
were emphasised most included WHO recommendations related to safety, effectiveness and efficacy 
of interventions, the country’s experience of malaria treatment policy change, the packaging, 
presentation and dissemination of evidence, coordination and harmonisation of the process and use 
of international scientific evidence and figures to engage positively in the dialogue.  
Barriers factors 
Interview respondents also identified factors that were barriers to decisions to adopt new malaria 
policy. These included:  
Financial sustainability 
The country cannot generate its own resources to sustainably fund new interventions from the 
national budget. Inadequate recurrent budgets have led to a dependency on donor funding. 
Sustainability of financing interventions is a challenge once when the donors withdraw their 
funding.  For instance, there are inadequate funds for vaccine operations at national level; the 
government contributes 5.4% of costs of vaccines. Specifically, the government covers the full 
costs of BDG, Measles, OPV and TT, while co-funds DPT-HEPB-HIB vaccine (as reported by ”IVD 
stakeholder”).  
Competing health and other priorities 
Given its limited resources, the government must choose from among competing health 
priorities and other national and local priorities. Scientific evidence should justify the need for 
new interventions and be ranked as a priority in the MOFEA agenda, according to the Member 
of Parliament;  
“It is important to understand why a particular intervention needs to be given priority, if there 
is treatment, prevention, larvicide, residual spraying and bed nets; all these are competing 
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interventions, they are competing for donor funding and donors have their own interests in 
funding” — (“Member of Parliament stakeholder”).  
Political will and bureaucratic procedures 
Any new interventions take time (2 – 3 years) to be understood and then accepted. Thus, 
planning for new interventions should start early to explore opportunities for engaging the 
government and donors, to take them on board, and to advocate and lobby for adoption. This 
is especially important in the context of government allocations for the roll out of malaria 
interventions and vaccines (“Bilateral & Multilateral partners stakeholders”) 
Costs related to the adoption and implementations of interventions 
All costs related to adopting and implementing interventions imply that large amounts of 
funds are spent on management activities rather than on actual implementation of 
interventions to achieve positive health outcomes (“NMCP Stakeholder”).  
Supply and distribution 
In some instances, global supply does not meet the demand for the malaria interventions,   
Interview respondents reported distribution issues arising from the logistics of transporting 
interventions from the manufacturer to the users. Other issues of concern include: whether 
the interventions need special transport and storage, how they are stored, availability of 
vehicles to facilitate transportation, and user friendly packaging of vaccines to facilitate 
delivery. Another important element is training. New interventions require development and 
roll out of an appropriate training package for health facilities (“NMCP, Bilateral donor 
Stakeholders”). 
Professional compliance with antimalarial drugs  
Access barriers related to affordability of interventions and competence of providers indicate 
that health infrastructure’s capacity must be increased so that clinicians comply with the 
recommended national policy and guidelines (“NMCP stakeholder”) These barriers are mostly 
influenced by: financial sustainability, competing priorities, political will and bureaucratic 
procedures, cost, supply and distribution and lack of compliance by users and health providers 
of the new malaria treatment policy.  
Actors  
With respect to the policy process for malaria interventions and vaccines, interview participants 
ranked stakeholders from most supporting to most opposing (Figure 2. Analysis of Key stakeholders 
interviewed below). In the process, different clusters of actors emerged, namely high supporters and 
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medium supporters, ranked as such on a scale of 0 – 8, where 0 is the lowest level of support.  
Analysis of key stakeholders interviewed indicated that the  actors with the highest power and 
position to support malaria vaccine adoption ranged from 6 – 7, while users, customers and AMANET 
were in the medium support category, ranked around 4 (Figure 2. Analysis of Key stakeholders 
interviewed below).  
 
Figure 2. Analysis of Key stakeholders interviewed 
Policy process 
This section presents respondent’s report on policy process for malaria interventions and 
vaccines. Findings are categorized into subthemes including: problem identification and policy 
formulation, agenda setting and partnership, policy implementation and operation and 
monitoring, evaluation and re adjustment.  
 Problem identification and Policy formulation  
Sometimes, the problem is identified by researchers or specific task force related to the 
subject matter. When scientific evidence is collected and established, with scientific proof 
from different sentinel sites, the evidence has to be systematically reviewed by a number of 
researchers to support the process for a policy change. Technical consensus on evidence-based 
information is built in consultation, through the technical advisory group, task force, experts, 
WHO and other malaria donors and policy makers. Several stakeholder meetings were 
conducted and presentations were made by experts.  A technical task force was formed as part 
of the process. The NMCP also engaged relevant stakeholders under the guidance of WHO to 
develop appropriate malaria treatment guidelines for the new policy (“NMCP, MOHSW, 
Bilateral & Multilateral partners stakeholders”).  
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Agenda setting and Partnership   
Politicians were more likely to introduce an issue into the policy agenda around a general 
election, when issues were compatible with other policy ideas, when there was a ‘window of 
opportunity’ (such as new or sudden availability of resources) and in times of crisis (“Bilateral 
& Multilateral partners stakeholders”)   
  Policy implementation and operational  
Planning for implementation begins when there is assurance of funding, therefore early 
identification and engagement of potential stakeholders to finance the new policy is important 
from the outset. Awareness and advocacy targeting the community who are the users of the 
intervention is advised. Relevant policy documents should be simplified so that they are 
understood by different groups of people. Service providers can sensitise users to 
interventions early to win support for relevant policy implementation (“NMCP, MOHSW 
stakeholders”).   
           Monitoring, evaluation and re adjustment 
Monitoring in policy development requires reviewing, planning and updating work on a regular 
basis and assessing whether activities are carried out as planned. For instance the IVD monthly 
progressive report on coverage, stock balance, surveillance sentinel sites and quarterly review 
meetings show the progress of implementation. These reports could be used as indicators 
against which to measure success in terms of process and health impact (IVD) (“IVD 
stakeholder”). 
Stages of policy development processes, simplified into four categories 
The analytical framework explains the policy process setting that is selected, as shown in Figure 3 
below. The framework explains the policy process for the forthcoming malaria vaccine and how 
stakeholders interact at different stages of the policy process. It describes how the stakeholders are 
involved and influence the policy process at each stage of the policy development process.  The 
stages of policy process as identified in Figure 3 include: problem identification and policy 
formulation, agenda setting and partnership, policy implementation and operation and policy 
monitoring, evaluation and re adjustment. Stakeholder ‘opinions vary and will shape the different 
stages of the policy process for the forthcoming malaria vaccine adoption and implementation in 
Tanzania. 
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Figure 3. Stages of policy development processes, simplified into four categories 
A. Problem identification and policy formulation 
B. Agenda setting and partnership  
C. Policy implementation and operation 
D. Monitoring, evaluation and re adjustment 
This practical result helps to construct the guideline (Chapter 6) 
The elements of the policy process presented were further analysed and are presented in Table 3 
below as they apply to policy change for new malaria interventions and vaccine adoptions in 
Tanzania. The study elements of the framework are; content, context, actors and processes.  The 
elements are grouped according to the policy process to facilitate understanding. 
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Table 3. Key elements of policy process for malaria interventions and vaccine adoptions in 
Tanzania  
Theme Subtheme & content 
Malaria treatment  
Subtheme & content 
Vaccine 
   Steps of content in decision-making 
Content  i)  Availability of evidence 
ii) Availability of intervention  
iii) Formation of Task force/technical 
groups to synthesize the evidence;  
package and translate evidence and 
cost implication 
iv) Presentation to the NMCP 
manager to convince him/her about 
the scientific evidence and the need 
for new intervention 
v)Presentation to the Director of DPS 
and Chief Medical Officers 
vi) Presentation to the MoHSW 
management team for approval 
i)Availability of evidence according 
to the (burden of disease and 
epidemiology data 
ii) Availability of intervention; 
Develop concept paper/ proposal 
iii) Scientific consultation with 
experts, researchers, health 
institutions and  development 
partners 
iv) Presentation to MOHSW 
management 
v) Presentation to ICC 
vi) Development of a 
comprehensive protocol for GAVI 
application 
Context   Promoting factors 
Epidemiological and 
intervention 
characteristics  
WHO-prequalification and 
recommendations for efficacy, safety 
and quality 
WHO-prequalification and 
recommendations efficacy, safety 
and quality 
Country experience  Adoption of decisions in neighbouring 
countries with similar settings as 
Tanzania 
adoption of decisions from 
neighbouring countries with similar 
settings as Tanzania 
Packaging and 
dissemination of 
information  
Translate the evidence in a manner 
that is digestible and understood to 
the policy makers. 
Translate the evidence in a manner 
that is digestible and understood to 
the policy makers. 
Coordination  and 
harmonization of the 
process 
Planning and harmonizing policy 
process  among government bodies 
and donors  
Planning and harmonizing policy 
process  among government 
bodies and donors 
Use of international 
scientific evidence 
 International stakeholders and 
donors take part in the dialogue from 
the onset and use their technical 
knowledge to clarify scientifically 
proven evidence in favour of the 
policy change 
International stakeholders and 
donors take part in the dialogue 
from the onset and use their 
technical knowledge to clarify 
scientifically proven evidence in 
favour of the policy change 
 
                                                         Barriers 
Financial sustainability Affordability of operational costs; 
availability of domestic financing, 
external financing; dependence on 
donor funding  during 
implementation of interventions and 
policies 
 Affordability of operational costs; 
availability of domestic financing, 
external financing; dependence on 
donor funding during 
implementation of interventions 
and policies 
 
Competing priorities Country’s competing health and 
other priorities  
 Country’s competing health and 
other priorities 
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Theme Subtheme & content 
Malaria treatment  
Subtheme & content 
Vaccine 
Political will and 
bureaucratic 
procedures   
It takes between two to three years 
to introduce new interventions 
It takes between two to three 
years to introduce new 
interventions 
Costs  Costs related to adopting and 
implementing interventions 
Costs related to adopting and 
implementing interventions 
Supply and distribution  Sometimes, global supply does not  
meet the  demand of the new 
intervention 
Sometimes, global supply does not 
meet the demand of the new 
intervention 
Professional 
compliance with 
antimalarial drugs 
Access barriers related to 
affordability of intervention and 
competence of providers 
 
                                                         Stakeholders  
Stakeholders   
 
NMCP managers; Director of 
Preventive Services (DPS), technical 
working group, MOHSW, MOF, the 
media, Professional organisations, 
development partners, TFDA, MSD,  
NIMR and IHI 
EPI managers, Director of 
Preventive Services (DPS), technical 
working group, MOHSW 
management team, MOF, the 
media, Professional organisations 
e.g MAT, development partners, 
GAVI, ICC, TFDA, MSD , NIMR and 
IHI 
                                                         Policy process  
Problem identification  
and policy formulation 
Understand the burden of disease 
and interventions to address burden 
of disease and the availability of 
alternatives 
Options and possible solutions are 
adopted  
Understand the burden of disease 
and interventions alternative  to 
address burden of disease and the 
availability of alternatives  
Options and possible solutions are 
adopted 
Agenda setting  Opportunity for funding, for instance 
NMCP wrote a proposal to the 
GFATM to support the introduction of 
SP in Tanzania  
 Opportunity for funding, for 
instance GAVI opened window of 
opportunity to finance vaccine 
Policy implementation 
and operation 
Planning for implementation begins 
when there is  assurance of funds; 
Policy activities are implemented 
 
Planning for implementation 
begins when there is assurance of 
funds; 
Policy activities are implemented 
Monitoring, evaluation 
and re adjustment  
Assessment of outcome and impact – 
Tanzania HIV and Malaria Indicator 
Survey (THMIS), Demographic Health 
Survey (DHS)   
EPI monthly progressive report on 
coverage, stock balance, 
surveillance sentinel sites and 
quarterly review meetings are used 
to assess the process and impact 
while the DHS assesses impact 
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The evidence drawn from elements of policy process and its importance based on review 
of literature:  
Content   
It is important to analyse the content of policy processes in the process of assessing policy 
options for introducing new interventions and their subsequent adoption.  We paid attention 
to the steps involved in the process to adopt policy decisions in favour of malaria treatment 
policy change interventions and vaccines in Tanzania and other African RTS,S study countries. 
Several findings confirmed the importance of a careful assessment of the policy process which 
will facilitate  the reform or policy change (Patton and Sawicki 1993; Green 2007).  
Context  
The contextual factors were analysed based on promoting factors and barriers for policy 
decision on new interventions. Promoting factors were; the characteristics of the 
interventions, packaging and dissemination of information, coordination and harmonisation of 
the process and use of scientific evidence. Barriers included; financial sustainability, competing 
priorities and political will and bureaucratic procedures. Several studies have identified 
barriers such as competing priorities and limited resources (Shiffman 2007), financial 
sustainability (G. Walt and Buse 2000) and political will (Munira and Fritzen 2007; Glassman et 
al. 1999; Reich 1995). The policy decision making process is dominated by political figures; 
their political will contribute to garnering political support for the policy decision to be made.  
Actors  
Interactions between actors and the other elements of policy process are given in Figure 3 
above. In this study, we identified the key actors and mapped their position to identify which 
groups are mobilized to support and influence the policy process. Studies have confirmed 
similar findings, that identifying potential allies and opponents can help develop strategies for 
seeking support for policy decisions (Varvasovszky and Brugha 2000; Reich 1995; Schmeer 
1999). Stakeholder analysis is one of the key tools used to facilitate policy decision making and 
eventual implementation (Brugha and Varvasovszky 2000). 
 Process 
The policy process is divided into four stages; problem definition and agenda setting is when 
the issue comes to the attention of decision makers; formulation stage is when the policies are 
enacted;  implementation stage is when policy activities are carried out; and the monitoring 
and evaluation stage assesses the impact (Gill Walt et al. 2008).  The Kingdon model explains 
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how issues get on the policy agenda. Policy is made through problem streams, politics streams 
and policies streams. When all these factors come together, the issue can achieve high agenda 
priority and create a window of opportunity for policy adoption (Kingdon and Thurber 1984). 
Windows of opportunity for financial commitments from international organisations, 
availability of new interventions such as the forthcoming malaria vaccine, and the high political 
commitment in the country towards malaria control could attract the demand for policy 
adoption.   
The elements of policy process considers the content of the policy, the actors involved in the process 
and the context in which the policy was developed and implemented,  process is concerned about 
how the issue gained policy priority and how the actors influence the process.  
Stakeholders were asked to reflect on the existing process of malaria interventions policy change and 
vaccines in Tanzania in order to identify key lessons learned for the forthcoming malaria vaccine 
implementation.  The following list represents what stakeholders perceived were the most salient 
“lessons learned”.  
 The potential malaria vaccine is a first generation malaria vaccine with a high probability of 
success at the Phase III stage; it targets specific age groups of children and is given as a 
consolidated package with other IVD vaccines.  
o  IVD has an established  infrastructure which can potentially  accommodate new 
vaccines; 
o  Factors for consideration are programmatic issues needed for a new vaccine, 
cold chain, training health workers, cost of introduction, funding opportunities 
available for the vaccine (GAVI).   
 Key concerns from the donor group and key questions generated 
o What are the operational costs of adding a new vaccine? 
o What are the potential sources of funding to deliver the vaccine? 
o How do you ensure supply meets demand for the vaccine? 
o How do you demonstrate operational and other costs to the donor partners? 
 Package and disseminate information about the malaria vaccine 
o Develop a package for the community who are users of the vaccine to let them 
understand exactly what the vaccine is capable of achieving.  Involves trainings 
and use of different types of media to facilitate adverts and advocacy.  
   Lobbying and advocacy 
o Any new interventions takes time (2-3 years) to be understood and then 
accepted, thus lobbying for the malaria vaccine should start now 
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o Advocacy should begin early enough as it takes time for people to understand and 
accept new interventions. Planning early will be important for the vaccine’s 
success.  
o Explore opportunities such as the development of new strategies (government 
and donors ) in which to include the malaria vaccine 
 The vaccine should be understood as a complementary intervention to existing malaria 
control measures such as ITNs, ACTs and diagnostics  
o Integrate malaria vaccine with other opportunities such as child health day, 
malaria campaigns in general, and use of advocacy avenues 
o To secure enough funding and involve other stakeholders  
 Planning, financing and implementation 
o There should be adequate analysis of the vaccine system in line with the 
introduction of the forthcoming malaria vaccine (storage, delivery, and 
packaging). 
 Integration and complementarity 
o Attention should be paid to the documents or guidelines to show how the 
vaccine relates to and complements other ongoing malaria interventions. 
o Consider options  for delivery at primary levels using existing interventions  e.g. 
the delivery of  a booster dose should be explored and documented in the 
implementation guidelines 
 Involvement of front line implementers 
o Sensitisation of health workers has to begin early enough to improve on 
motivation and any negativity projected from them to community.  
o Involvement of health workers can be done through several, small gestures. For 
example, holding meetings between Council Health Management Teams 
(CHMTs) and health workers when they conduct supervision, informing and 
advising them to accept a new vaccine. 
 Continuity and sustainability: 
o Have a clear plan of what the funding sources would be after GAVI support ends 
o Use opportunity to develop new health-related strategies to include the vaccine 
so that it is considered in funding 
o Ensure that there will be enough production so that procurement will not be 
affected by low production 
The forthcoming malaria vaccine is viewed positively and the evidence accrued to date shows that it 
integrates well with the vaccine immunization programme. The introduction of a malaria vaccine has 
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no apparent negative impact on elements of the frameworks analysed. It is perceived as increasing 
opportunities to reach vulnerable children.  The IVD programme is ready and capable of 
accommodating a new vaccine. The immunization programme has strategies for handling all related 
issues such as cold chain capacity, human resources, training, advocacy, revision of guidelines and 
reporting system on adverse events. Their preparedness enhances the value of ensuring all the 
groundwork is thoroughly reviewed before a malaria vaccine is introduced.  
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4.5  Discussion 
The framework method has been developed and used widely in many countries and to address a 
variety of health policy concerns (Gilson and Raphaely 2008)  The policy framework combines the 
concepts of content, context, actors and process to understand the policy process and to plan for 
effective implementation of interventions  (G. Walt and Gilson 1994). The policy framework in this 
study built on the literature and was based on experiences and observations of the policy process 
and the factors influencing policy decisions in Tanzania. It was used to organise information in a way 
that explains the drivers of policy change and to gauge understanding and lessons learnt from the 
introduction of new malaria interventions through policy change. The framework also described the 
potential for introducing a malaria vaccine and other vaccines in the health system while critically 
observing policy formulation and implementation. The framework approach has its limitations. It 
highlights some information while minimising or excluding others  (Coker et al. 2010).  Here, we left 
out some parts of the framework or elaborated others to a lesser extent in order to focus on aspects 
that are relevant to the study context (Hercot et al. 2011).The framework may or may not be 
applicable to other low-income countries with similar contexts. Its applicability depends on whether 
the policy is appropriate to the needs of a specific country and is feasible in a low-resource settings 
(G. Walt and Gilson 1994). 
The framework is feasible and can be used in the Tanzanian context. Although Tanzania has not yet 
introduced a malaria vaccine, the framework contributes to understanding a very complex and highly 
political subject – policy analysis. It assists in unpacking the national level discussion, involving 
evidence-based information, stakeholders’ interactions, and political commitment; factors that are 
all important for planning the forthcoming malaria vaccine.  
The framework was also applied to African countries that had conducted RTS,S malaria vaccine 
clinical trials. Among these are Burkina Faso, Ghana, Gabon, Mozambique, Malawi and Kenya (Table 
4); none of these countries have introduced the malaria vaccine yet. The framework acknowledges 
the diversity of experiences across those countries.  We have tried to analyse each country with 
regard to content and context, and we had to rate each country with regard to its readiness for 
adoption of forthcoming malaria vaccine. The reference for our ratings was previous malaria 
treatment policy change. We applied semi-qualitative ratings of health systems’ readiness for malaria 
treatment policy change. Discussion is based on a summary of the content-and contextual-related 
steps in decision making (promoting and barriers factors: Error! Reference source not found.). It is 
interesting to note that Tanzania, Burkina Faso (Panisset et al. 2012);  Gabon (Nsimba et al. 2008); 
Malawi (Malenga et al. 2009) and Kenya (Williams, Durrheim, and Shretta 2004; Amin et al. 2007; 
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Okungu and Gilson 2014) seemed to be well prepared with regard to content factors (agreed 
scientific evidence).   
Promoting factors such as safety and efficacy, WHO protocol and decisions adopted in other 
countries were noted in Burkina Faso (Panisset et al. 2012; Kouyaté et al. 2007), Ghana (Duah et al. 
2013), Gabon (Nsimba et al. 2008), Malawi (Malenga et al. 2009) and Kenya (Amin et al. 2007).  
Harmonization of the policy process across departments and collaboration between policy makers 
and scientists were identified in Burkina Faso (Panisset et al. 2012) and Malawi (Malenga et al. 2009). 
The importance of technical assistance from WHO and other interested donors were also identified 
in  Burkina Faso (Panisset et al. 2012), Gabon (Nsimba et al. 2008), Malawi (Malenga et al. 2009) and 
Kenya (Amin et al. 2007). Among the identified barriers were the lack of sustainable financing in 
Burkina Faso (Kouyaté et al. 2007),Gabon (Nsimba et al. 2008) and Kenya (Amin et al. 2007); and 
non-adherence to treatment in Burkina Faso (Kouyaté et al. 2007), Mozambique (Cliff et al. 2010) 
and Kenya (Amin et al. 2007). Effective communication supporting the correct use of medicines can 
counteract non-adherence and use of in-effective medicines  (Okungu and Gilson 2014; Mbofana, 
Machatine, and Moreira 2010). It can also be done through engaging the private sector and 
encouraging hospitals and pharmacies to adhere to national guidelines (Panisset et al. 2012).  
The semi qualitative assessment (rating of malaria policy change) shows that most African RTS,S 
countries seemed to be ready for adoption of the forthcoming malaria vaccine.  Tanzania seems to 
be well prepared with regard to both promoting factors ((12), very good) and well-documented 
barriers. It is interested to note that Burkina Faso seems to be well prepared with regard to content 
and policy promoting factors ((10), good). It does not, however, have well-documented information 
on barriers. Similarly, Malawi seems to be well prepared with regard to policy promoting factors ((9), 
good) but lacks documented information on barriers.  Kenya and Gabon are also prepared with 
regard to policy promoting factors (++ (8), good) but neither have sufficient documented information 
on barriers.  Ghana is also prepared with regard to policy promoting factors, scores poorly on policy 
promoting factors ( (5), little) and on documented information on barriers and Mozambique also 
scores low on promoting factors and documented barriers ((1) , weak). The rating implies that 
Burkina Faso, Malawi, Kenya and Gabon are prepared to embark on adoption of the forthcoming 
malaria vaccines RTS, S. Ghana and Mozambique are not well prepared, which implies a need of 
study to understand those factors before a policy decision is made on RTS, S adoption.  The attempt 
to synthetically compare all African RTS, S countries shows that a “good” or “very good” ranking on 
promoting factors may not automatically translate to action due to some mentioned and 
documented barriers. 
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Table 1. contextual factors influencing the introduction of RTS,S vaccine in different countries 
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Conclusion and Recommendations  
The framework is used at the national level, while overall policy recommendation is made at the 
global level. We can use the framework once the global policy is articulated and treat it as an 
operationalized statement. The framework is a comprehensive tool that enables one to unpack the 
content and contextual factors surrounding the decision to introduce a potential malaria vaccine in 
African RTS, S countries. Furthermore, the framework provides an effective way to deepen our 
knowledge of the policy process and to inform the policy decision-making process for new malaria 
interventions, generally, and for the forthcoming malaria vaccine, specifically. It is an applicable and 
appropriate tool for African RTS,S countries and other low resourced settings. Lastly, the framework 
facilitates the synthesis of information in a coherent way, enabling a clearer understanding of the 
policy process, thereby speeding up the policy decision-making process and shortening the time until 
the forthcoming malaria vaccine becomes available. While we find the framework useful and 
applicable, we still feel that further validation is required. 
The framework is appropriate and recommended for various settings depending on the availability of 
content and contextual (promoting and barriers factors) information to inform the policy decision 
process. It can be useful as a step in the direction of research that supports better formulation and 
implementation of malaria interventions policies in African RTS, S countries.    
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5. Discussion, Conclusions and Recommendations 
5.1 Discussion  
The thesis attempts to analyse policy issues that are especially relevant to policy decisions around 
intervention adoption. The analysis assessed parental perception of a malaria vaccine and policy 
analysis frameworks for deciding on a malaria vaccine in Tanzania, and considered implications for 
other African RTS,S countries. Detailed discussions of the findings are provided in their respective 
chapters. This section begins with detailed discussion of the methodology used and the lessons 
learnt. It is followed by a discussion of the main findings and its implications with reference to the 
objectives described in chapter 4. The thesis wraps up with policy recommendations and the main 
conclusions. 
5.1.1 Methodology and study design  
In undertaking this study, several approaches were used. A cross-sectional study was conducted 
during the Tanzanian Integrated Measles Campaign (IMC) survey, which provided a chance to 
document and reflects on future malaria vaccine adoption. One study assessed awareness of and 
willingness to use a malaria vaccine (Chapter 3). Another study documented the use of a policy 
analysis framework for deciding on malaria vaccine in Tanzania and its implications for other African 
RTS,S countries.  Document review and qualitative research tools were used and the policy analysis 
framework was applied to African countries where malaria vaccine RTS,S clinical trials were 
conducted to assess malaria treatment policy changes and to draw lessons for malaria vaccine 
adoption (Chapter 4). Each of the methods used in the study had their strengths and limitations as 
explained in the paragraphs below. 
Since the start of this study, three studies on community perceptions of malaria vaccines have been 
published, using different approaches. The studies are from Ghana  (Febir et al. 2013), Mozambique 
(Bingham et al. 2012) and Kenya (Ojakaa et al. 2011). The method for selecting intervention and 
study areas was different in all three studies.  In Ghana, the study  (Febir et al. 2013) used qualitative 
and quantitative surveys, conducted in two districts.  For the qualitative survey, participants were 
selected based on specific criteria included women and men whose children had or had not 
participated in RTS,S malaria vaccine trial. In total, 12 focus group discussions (FGDs) and 15 in-depth 
interviews (IDIs) were conducted.  The quantitative survey involved 466 men and women from 
selected communities involved in the qualitative study. A systematic sampling method was used.  
Half of the respondents had been involved in the RTS,S malaria vaccine trial phase II. A structured 
questionnaire was developed based on the same themes and variables covered in the qualitative 
survey (Febir et al. 2013).  The study in Kenya (Ojakaa et al. 2011) was a qualitative study, conducted 
in two malaria-endemic regions. Similar to the Ghana study, participants were selected based on 
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specific criteria. Study sites were selected based on malaria endemic and community support for the 
study.  A total of 20 focus group discussions were held, with 234 participants; 22 in depth interviews 
and 18 exit interviews were also conducted (Ojakaa et al. 2011). The Mozambique study (Bingham et 
al. 2012) was a qualitative study, conducted in two malaria-endemic districts that did not host 
malaria vaccine clinical trials. The districts were accessible from Maputo during rainy season when 
the study was conducted and reflected geographic and cultural diversity. Participants were selected 
based on specific criteria, while sites were selected based on malaria endemicity and community 
support for the study.  A total of 23 focus group discussions were held, with 250 participants; 26 in 
depth interviews were also conducted (Bingham et al. 2012).  
The Kenya and Mozambique studies used similar qualitative study designs. The approach explores 
and seeks to understand the meaning that individuals attribute to a social or human problem 
(Creswell 2013; Driscoll et al. 2007). Such an approach is simple and cheap, and has the advantages 
of being able to define individual perceptions and attitudes. The conclusions are drawn from 
individually based data.  It was convenient for the studies’ small sample sizes. The study in Ghana 
used a mixed methods (qualitative and quantitative) approach. The advantage of this approach is 
that the qualitative data provides a deep understanding of responses, while statistical analysis 
provides a detailed assessment of patterns of responses. Combing the two methods can be time 
consuming and expensive, and usually requires reducing the sample size or limiting the time spent on 
interviews  (Driscoll et al. 2007).  
The current study was part of a large cross-sectional study using random sampling probability in 23 
regions of Tanzania, with a study population of 5,502 women, aged 18 years or older and with 
children under 11 months old.  The minimum sample size was 270 mothers in each region. The study 
benefited from being part of a big country-wide survey conducted during the Tanzanian Integrated 
Measles Campaign (IMC). The design increased the power of the study by using a large sample size. 
The survey evaluated the status of immunization coverage. It generated information on routine 
vaccination coverage that would be useful to predict the future uptake of malaria vaccine coverage, 
as the malaria vaccine is expected to be delivered through the immunization programme. It is a 
feasible study design with regards to the logistics needed to conduct a large study. It provides the 
opportunity to apply the lessons learnt from the study conducted in communities where RTS,S 
malaria vaccine trials were carried out, compared to the communities that did not participate in 
malaria vaccine trials as well as a comparison of the study regions with high malaria transmission and 
low malaria transmission.  It helps to monitor adverse events in both low and high transmission 
areas.  
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5.1.2 Main findings and its implications 
Understanding community perceptions of a malaria vaccine can help plan interventions and  identify 
policy issues that could be hinder the introduction and implementation of a malaria vaccine (Febir et 
al. 2013). Our findings were similar to those found in Ghana and Kenya showing wide spread 
knowledge of the benefits related to childhood vaccinations (Febir et al. 2013; Ojakaa et al. 2011). 
Malaria vaccine was perceived to be a preventive tool against malaria (Febir et al. 2013; Ojakaa et al. 
2011).  Overall, our findings showed a low level of awareness and a high willingness to use a malaria 
vaccine. The malaria vaccine is new and many have yet to learn about it. There is no previous 
experience of using a malaria vaccine.  The availability of evidence helps to make informed decisions 
about introducing a malaria vaccine within the Tanzanian health systems (Brooks and Ba-Nguz 2012). 
The policy process is complicated and involves different steps of decision making. Different factors 
influence or must be considered at each step.  
5.2 Global policy recommendation  
Policy recommendations for a malaria vaccine have been initiated at the global level, where the Joint 
Technical Expert Group (JTEG) serves as an evidence-assessment working group. The JTEG report will 
be reviewed by SAGE and MPAC, who will then make recommendations.  JTEG recommended use of 
RTS,S malaria vaccine in children 5-17 months within all transmission settings.  WHO has indicated 
that a policy recommendation advocating RTS,S malaria vaccine use would be implemented in 
countries through the World Health Organization’s IVB (formerly EPI).  SAGE comments on feasibility 
considerations, including scheduling and booster doses. JTEG recommends a booster dose 
administered between 15-18 months. The IVB schedule is already overburdened but there is a 
programmatic advantage to spreading out the booster schedule at that age because IVB routine 
vaccinations are completed by nine months.  A booster dose is essential to increase vaccine efficacy 
and its feasibility must be considered when planning vaccine introduction with the aim of maximizing 
coverage. Countries should strengthen their pharmacovigilance systems, not only for febrile seizures 
and meningitis, but also for other adverse events occurring frequently.  The feasibility of sub national 
vaccine implementation strategies depends on the capacity of the IVB programme.  MPAC concerns 
are based on integrating the new vaccine with other malaria control strategies, that is to say that the 
introduction of a malaria vaccine should not affect the sustained coverage of other malaria control 
strategies. The NMCP should strengthen malaria surveillance prior to and in conjunction with the 
planned malaria vaccine introduction to allow for continued monitoring of malaria disease trends 
and of the vaccine’s impact on coverage of malaria interventions.  Cost effective analysis includes 
considerations such as age distribution of cases, cost of the vaccine and cost of new visits that may 
not support its use.    
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5.2.1 Implication of global recommendations to Tanzania  
Malaria vaccine RTS,S is the first vaccine to show signs of protection and reduce episodes of clinical 
malaria by half among children 5-17 months old when used in conjunction with other malaria control 
strategies such as ITNs and anti-malarial drugs (Asante et al. 2011; Agnandji et al. 2011; Ojakaa et al. 
2011; Abdulla et al. 2008).  Therefore, a licensed vaccine has important potential to protect under 
five children.  In Tanzania, the malaria vaccine is expected to be delivered through the IVD 
programme and implemented at facility level by health care providers in both private and public 
facilities. Although; IVD is a robust system capable of implementing the malaria vaccine, there are a 
number of challenges that need to be addressed, including weak vaccine pharmacovigilance, 
inadequate personnel and expansion of storage capacity.  Currently cold room and storage capacity 
needs to be expanded at all levels (national, zonal, regional, district and facility) to accommodate 
malaria vaccine storage and transportation.  Cold rooms are available at national, zonal and regional 
levels, while the cold chain is maintained by refrigerators at district and facility levels.  At district 
level, refrigerators are electric, while those at facility levels are gas operated. Several facilities 
reported frequent shortages and hence a breakdown of the cold chain.  There is a need to procure 
back-up power, such as generators and solar systems.  Currently, the storage capacity at the national 
level is sufficient for six months’ storage, with back up space for a 25% buffer stock. At the regional 
level, capacity is sufficient for four months’ storage with back up space for a 25% buffer stock and 
255 space capacities for storage of other drugs.  At district level, storage is sufficient for three 
months. At facility level, they can maintain a monthly supply with two weeks’ extra supply (Tanzania 
EPI Report 2010). Malaria vaccine delivery should be operationalized through technical staff at IVD.  
Lack of human resource is a problem throughout the health sector, especially in public services. At 
national level, only 35% of the required staffing levels have been filled. The inadequacy of human 
resources in both numbers and skill could be a key challenge to delivering the malaria vaccine 
through IVD services. Introduction of a malaria vaccine will add to the already burdened workforce, 
and the impact of this additional workload need to be analysed to develop a strategy to mitigate the 
situation (Tanzania EPI Report 2010).  It is proposed to schedule the malaria vaccine at five, six and 
seven months and possible booster dose at 18 months together with second Measles vaccine. This 
strategy will lessen the workload as only one vaccine will be given on a single visit. Guidelines, 
documents and training materials should be modified to harmonize IVD programme and malaria 
vaccines and be made available for circulation to those working in immunization services. Public 
awareness and demand for safety of drugs and vaccine innovations need to be maintained both 
during trials and post licensure (Chen et al. 2001; Darwish 2000).  Despite having been approved 
after undergoing clinical trials and post approval phase IV trials, monitoring systems need to be in 
place for continuous surveillance of adverse events. The IVD’s vaccine pharmacovigilance is weak 
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(Tanzania EPI Report 2010), thus it should be strengthened in collaboration with the TFDA by 
establishing or strengthening reporting systems to give feedback on adverse events. Vaccines are 
considered cost effective interventions that are easy to administer, monitor and evaluate. The main 
determinant for implementing the malaria vaccine is its cost effectiveness compared with other 
existing malaria interventions. Cost effectiveness analysis provides information for identifying 
interventions that represent the best value for money, essential for setting priorities  in low 
resourced settings (Goodman, Coleman, and Mills 1999). A documented study in Tanzania on the 
costs of introducing a malaria vaccine (Hutton and Tediosi 2006) estimated the cost of delivering a 
malaria vaccine through IVD programme as ranging from USD 1 -10 per dose; at a vaccine price of 
USD 1 per dose, the total annual cost of delivering malaria vaccines through IVD programme would 
be more than 35% of the current budget. When the vaccine price increases, the total annual cost 
would also increase (Hutton and Tediosi 2006).  Additional resources should be mobilized and 
directed to the IVD programme to enable them to deliver the malaria vaccine in conjunction with 
other IVD vaccines.  
5.3 General Conclusions 
The main conclusions from the study were as follows:  
1. Malaria is still a national priority that requires to optimal use of all malaria control tools 
available because it is still a public health problem. 
2. There is a relatively high willingness among communities to use a malaria vaccine to 
complement other existing malaria interventions 
3. The vaccine’s acceptability matches the recently reinforced global strategy to promote policy 
recommendations in favour of malaria vaccine use.  
4. Any introduction of a new intervention, in our case, has to follow a structured process of 
decision-making, as described in the framework, in order to succeed.  
5. The prime steps are to answer questions of cost effectiveness, programmatic feasibility and 
potential integration with other malaria control strategies.  
6. As malaria vaccine RTS,S is expected to be delivered through IVD programme,  IVD services 
must be examined and made sufficiently robust to accommodate the malaria vaccine. IVD 
services appear capable of supporting malaria vaccine delivery; however IVD programme 
requires expansion of storage capacity, which can only be determined once the package of 
the malaria vaccine is known. IVD programme also needs capacity strengthening for health 
workers (immunization), revised guidelines and documents to harmonize the malaria vaccine 
with IVD services, and strengthened reporting system for any adverse events associated with 
the malaria vaccine. 
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7. Studies have documented RTS,S malaria vaccine is cost effective, more work is needed to 
determine its cost effectiveness. 
8. Although the malaria vaccine is proven effective, a major challenge to policy adoption will be 
to obtain support from stakeholders particularly at the local and national levels.  
5.4 Guideline for recommendations 
1. In Tanzania, the malaria vaccine is expected to be delivered through Immunization and 
Vaccine Development (IVD) programme and to be implemented at facility level by health 
care providers in both private and public facilities.  
2. Propagate the policy through awareness creation on the policy statement 
o Advocate for increased resources to implement communication plan 
o Develop a communication plan to demonstrate with evidence how the malaria 
vaccine will contribute to attaining public health outcomes 
o Make  information about the intervention accessible to target communities; it should 
be easy to read and understandable 
o Deliver communication materials that show parents with their children to champion 
malaria vaccination. 
o Use media to champion the malaria vaccination through accurate reporting on 
prominent stories related to the malaria vaccine. 
o Use the IVD platforms (clinics, entertainments shows) to advocate for delivering a 
malaria vaccine. 
3. Partnership can be created at the global, national and sub national levels.    
 At the Global level  
o Make inquiries and agreements to build confidence that a global vaccine market and 
supply is assured, affordable and easily incorporated.  
o Liaisons between MSD clearing departments and IVD with GAVI to ensure that 
vaccine is delivered on time.  
 At the national level 
o Advocate for increased resources to address programmatic limitations issues (expand 
storage and transportation capacity of IVD programme once the package of malaria 
vaccine is known). 
o Encourage IVD to procure more generators to ensure back up of power for cold 
rooms as a preparatory step towards accommodating the new malaria vaccine. 
o Plan early to incorporate co-financing levels into the national budget to prepare for 
financing malaria vaccine acquisition and distribution; it is still not known whether 
the malaria vaccine will be funding by government or GAVI co financing.  
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o Modify guidelines, documents and  training materials for immunization services that 
show how IVD and malaria vaccines could be delivered together 
o Operationalize the process through training technical staff at IVD on procedures and 
on identifying shortages.  
o Training of health care personnel involved in vaccination to understand the 
intervention (malaria vaccine) in order to maintain quality of services delivered.   
o Establish a special surveillance system to monitor vaccine pharmacovigilance. Based 
on the experience of this surveillance, adjust and modify operational guidelines as 
new issues arise.  
o Identify where the vaccine will launch (districts, regions and zones); it will help to 
assess the side effects in areas with low and high malaria transmission. 
o Establish adverse events plans, particularly monitoring febrile seizure and meningitis.  
o Incorporate flexibility to adjust administration of booster dose to maintain vaccine 
efficacy. 
 Sub  national level 
o Ensure partnership with IVD and district health services. The district is a very 
important level in the provision of health services in a decentralized system.  
o Establish a special surveillance system to monitor vaccine pharmacovigilance.   
o Strengthen the malaria surveillance system to allow for monitoring of malaria disease 
and vaccine impact. 
5.5 Recommendations for future research 
               Operational research and evaluation  
o Conduct a feasibility study to assess the required storage capacity of IVD and 
package of RTS,S malaria vaccine to accommodate malaria vaccine delivery. 
o Carry out a situational analysis to identify the required numbers and skills of 
human resources 
o Conduct workload analysis  for health care workers involved in vaccination  
o Conduct post licensure studies to follow up on safety, effectiveness and impact at 
sentinel sites with demographic surveillance systems linked to immunization  
o Assess vaccine pharmacovigilance of malaria vaccine in low and high malaria 
transmission settings 
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Appendix 1: Number of women with children 0 – 11 months interviewed  
Country / Region Number 
TANZANIA 5502 
ARUSHA 32 
DAR ES SALAAM 239 
DODOMA 306 
IRINGA 291 
KAGERA 243 
KIGOMA 236 
KILIMANJARO 253 
LINDI 228 
MANYARA 269 
MARA 118 
MBEYA 270 
MOROGORO 242 
MTWARA 237 
MWANZA 283 
PWANI 250 
RUKWA 243 
RUVUMA 262 
SHINYANGA 250 
SINGIDA 261 
TABORA 280 
TANGA 181 
MAINLAND 4974 
UNGUJA 298 
PEMBA 230 
ZANZIBAR 528 
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Appendix 2: Percentage distribution of all women, of perceived awareness of and willing 
to use malaria vaccine by country / region 
Country / Region  Awareness Willingness 
TANZANIA 11.0 (607/5502) 94.5 (5,201/5,502) 
ARUSHA 12.5 (4/32) 87.5 (28/32) 
DAR ES SALAAM 2.9 (7/239) 97.1 (232/239) 
DODOMA 4.3 (13/306) 89.5 (274/306) 
IRINGA 0.3 (1/291) 89.0 (259/291 
KAGERA 2.1 (5/243) 94.2 (229/243) 
KIGOMA 5.9 (14/236) 95.8 (226/236) 
KILIMANJARO 2.4 (6/253) 95.3 (241/253) 
LINDI 6.1 (14/228) 94.3 (215/228) 
MANYARA 68.4 (184/269) 83.3 (224/269) 
MARA 33.1 (39/118) 90.7 (107/118) 
MBEYA 3.7 (10/270) 97.4 (263/270) 
MOROGORO 6.2 (15/242) 97.9 (237/242) 
MTWARA 8.0 (19/237) 97.5 (231/237) 
MWANZA 15.2 (43/283) 98.9 (280/283) 
PWANI 6.8 (17/250) 97.2 (243/250) 
RUKWA 16.5 (40/243) 97.9 (238/243) 
RUVUMA 5.7 (15/262) 90.1 (236/262) 
SHINYANGA 32.8 (82/250) 95.2 (238/250) 
SINGIDA 11.1 (29/261) 98.1 (256/261) 
TABORA 9.3 (26/280) 97.1 (272/280) 
TANGA 3.3 (6/181) 89.0 (161/181) 
MAINLAND 11.8 (589/4974) 94.3 (4,690/4,974) 
UNGUJA 1.7 (5/298) 97.7 (291/298) 
PEMBA 5.7 (13/230) 95.7 (220/230) 
ZANZIBAR 3.4 (18/528) 96.8 (511/528) 
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Appendix 3: Percentage distribution of perceived benefits related to under-five child 
vaccinations, mode of administering malaria vaccine and perceived acceptance of sending 
the child for malaria vaccine on proposed schedule 
Country / Region Benefits Delivery mode Proposed schedule 
TANZANIA 88.4 (4,864/5502) 81.3 (4,473/5,502) 86.7 (4,772/5502) 
ARUSHA 75.0 (24/32) 62.5 (20/32) 87.5 (28/32) 
DAR ES SALAAM 94.1 (225/239) 83.3 (199/239) 90.8 (217/239) 
DODOMA 86.9 (266/306) 85.0 (260/306) 90.2 (276/306) 
IRINGA 58.1 (169/291) 83.2 (242/291) 78.0 (227/291) 
KAGERA 94.7 (230/243) 87.2 (212/243) 92.6 (225/243) 
KIGOMA 86.4 (204/236) 88.1 (208/236) 96.2 (227/236) 
KILIMANJARO 92.5 (234/253) 90.5 (229/253) 91.7 (232/253) 
LINDI 95.2 (217/228) 90.4 (206/228) 93.4 (213/228) 
MANYARA 72.9 (196/269) 75.8 (204/269) 77.0 (207/269) 
MARA 89.0 (105/118) 85.6 (101/118) 86.4 (102/118) 
MBEYA 97.0 (262/270) 90.0 (243/270) 93.0 (251/270) 
MOROGORO 92.6 (224/242) 73.1 (117/242) 93.4 (226/242) 
MTWARA 94.1 (223/242) 78.9 (187/237) 94.9 (225/237) 
MWANZA 98.6 (279/283) 93.3 (264/283) 71.0 (201/283) 
PWANI 92.0 (230/250) 88.0 (220/250) 82.0 (205/250) 
RUKWA 97.5 (237/243) 97.1 (236/243) 95.9 (233/243) 
RUVUMA 86.6 (227/262) 38.9 (102/262) 84.0 (220/262) 
SHINYANGA 91.2 (228/250) 66.8 (167/250) 60.8 (152/250) 
SINGIDA 90.4 (236/261) 83.9 (219/261) 92.7 (242/261) 
TABORA 96.1 (269/280) 95.4 (267/280) 94.3 (264/280) 
TANGA 63.5 (115/181) 81.2 (147/181) 76.8 (139/181) 
MAINLAND 88.5 (4400/4974) 82.6 (4,110/4,974) 86.7 (4,312/4,974) 
UNGUJA 88.6 (264/298) 75.2 (224/298) 86.6 (258/298) 
PEMBA 87.0 (200/230) 60.4 (139/230) 87.8 (202/230) 
ZANZIBAR 87.9 (464/528) 68.8 (363/528) 87.1 (460/528) 
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Appendix 4: Tool used to collect information on women’s behavioural aspects related to 
vaccine and malaria Vaccine, Tanzania 
A: General Information 
District |__|__| 
Division |__|__|__|__|__|__|__|__|__|__|__|__|__| 
Ward |__|__|__|__|__|__|__|__|__|__|__|__|__| 
Village |__|__|__|__|__|__|__|__|__|__|__|__|__| 
Sub-village  |__|__|__|__|__|__|__|__|__|__|__|__|__| 
Cluster number |__|__|__|__| 
Household Number |__|__|__| 
Date  of last born child (Date / Month / Year) |__|__|/|__|__|/|__|__|__|__| 
Date of interview  (Date / Month / Year) |__|__|/|__|__|/|__|__|__|__| 
Time to start: Hours: Minutes |__|__|:|__|__| 
Time to finish: Hours: Minutes  |__|__|:|__|__| 
Respondent Number     |__|__|__|__|__|__|__|__|__|__|__|__|__|__|__|__|__|__|__| 
B: Status of the interview  
1 What is the status of the interview?  (1) Complete  
(2) Incomplete  
(3) No interview  
2 If incomplete or no interview, why? (1) Verbal Consent not given   
(2) Verbal Consent refused  
(3) Other  
(4) Specify_______________________  
 
C: GENERAL KNOWLEDGE 
1 Apart from under-five child diseases with 
routine vaccination (TB, Polio, Measles 
and Hepatitis B, Diphtheria, Pertussis, 
Tetanus), which other health related 
problems do you consider to be serious 
in your community? (list up to five 
illnesses/diseases) 
(1) ____________________________________ 
(2) ____________________________________ 
(3) ____________________________________ 
(4) ____________________________________ 
(5) ____________________________________ 
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2 Which illnesses/diseases you have 
mentioned above, do you propose them 
for vaccination? 
(1) ____________________________________ 
(2) ____________________________________ 
(3) ____________________________________ 
(4) ____________________________________ 
3 Do you know of any benefits related to 
under-five child vaccination?   
(1) Yes                     
(2) No                      
4 If yes, list them (1)  ___________________________________ 
(2) ____________________________________ 
(3) ____________________________________ 
(4) ____________________________________ 
 
 
 
5 What motivated you, for taking your 
child for vaccination? 
   
 
 
D: MALARIA 
1 Do you know any malaria 
prevention strategies? 
(1) Yes                      
(2) No                      If No move to D3 
2 If yes, list all methods of preventing malaria. Please mention all that you can think of. (Check all 
that are mentioned). Which do you use at home? 
  Methods of preventing malaria   Mentioned Home use 
ITN (bed-nets) use for children   
Residual spraying with insecticide       
Intermittent preventive treatment (IPTi)     
Drainage of mosquito breeding sites    
Block mosquito entry inside homes   
Plugging holes, closing windows/doors   
Burn things to create smoke inside house   
Cleaning environment around house      
Other____________________________________   
3 Have you ever heard about malaria vaccine? (1) Yes                     
(2) No 
4 If yes, where did you hear from?  
5 Suppose a malaria vaccine could soon become available for under-five children in your 
community. I am now going to give you some information about the vaccine. After I read each 
statement, please tell me the extent to which you agree with the statements. 
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 A. Do you believe that malaria vaccination will bring any benefits related to under five child 
health?                                               Yes/No/Not sure 
 B. As Malaria vaccine will prevent cases of diseases; would you like your child to get the 
vaccine?                                             Yes/No  
 A. The vaccine can prevent many children from getting malaria. 
  5) Strongly agree        4) Agree     3) Not sure       2) Not agree        1) Strongly disagree 
 B. The vaccine causes discomfort similar to other childhood vaccines 
5) Strongly agree        4) Agree     3) Not sure       2) Not agree        1) Strongly disagree 
 C. The vaccine will be given at the same health facility and at the same time as other childhood 
vaccines. 
5) Strongly agree        4) Agree     3) Not sure       2) Not agree        1) Strongly disagree 
 D. The malaria vaccine may require 2-3 jabs to receive full benefit. 
5) Strongly agree        4) Agree     3) Not sure       2) Not agree        1) Strongly disagree 
 E. Even though a child is vaccinated, s/he could still get malaria. 
 5) Strongly agree        4) Agree     3) Not sure       2) Not agree        1) Strongly disagree 
 F. A vaccinated child who gets malaria will still need to receive treatment. 
5) Strongly agree        4) Agree     3) Not sure       2) Not agree        1) Strongly disagree 
 G. Even though a child is vaccinated, s/he still has to sleep under ITN. 
5) Strongly agree        4) Agree     3) Not sure       2) Not agree        1) Strongly disagree 
 H. The vaccine would prevent severe malaria in a vaccinated child. 
5) Strongly agree        4) Agree     3) Not sure       2) Not agree        1) Strongly disagree 
 
E: PNEUMONIA AND DIARRHOEA 
1 Do you consider pneumonia is serious 
disease among under-five children in your 
community? 
(1) Yes                      
(2) No                     
 
2 Do you suggest pneumonia vaccine to be 
provided too?  
(1) Yes                      
(2) No                      If No, then skip to E4 
3 If yes, will you accept your child to be 
vaccinated with pneumococcal vaccine 
too? 
(1) Yes                     
(2) No                       
4 
Do you consider diarrhoea is serious 
disease among under-five children in your 
community?  
(1) Yes             
(2) No              
5 Do you suggest diarrhoeal vaccine to be (1) Yes                If No, then Finish 
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provided too?  (2) No                     
6 
If yes, will you accept your child to be 
vaccinated with diarrheal vaccine too? 
(1) Yes                     
(2) No                     
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 Appendix 5: Interview Guides 
Landscape Analysis of National Policy Decision Process for Adopting the RTSS vaccine – Tanzania 
Interview guide for policy making with regard to policy processes of past malaria intervention and for 
the RTSS vaccine 
Introduction  
Ifakara Health Institute (IHI) and National Institute for Medical Research (NIMR) have been at the 
center of clinical trial efforts in the development of malaria vaccines. At the end of the on-going 
clinical trials for malaria vaccines; policy makers would need to be provided with scientific advice on 
whether to adopt the vaccine or not. 
To achieve this, it was considered important to share the experience of the decision making process 
for adoption of other malaria interventions and vaccines in the country. Knowledge of the country’s 
pathway for decision making on adopting vaccines will shed light on the implications for a malaria 
vaccine if a malaria vaccine is ultimately licensed.  
(1) Over the last decades, scientists have made tremendous progress in the development of 
malaria vaccine and the world leading vaccine candidate – the GSK BIO RTS,S – has entered  
the last phase of clinical trials.  
What is the opinion of the Tanzanian Government on the development of malaria vaccine? 
Prompts 
- Does the Government consider it an appropriate intervention strategy? 
- What is the stand of the Government in terms of possible adoption? 
- What are the reservations the Government has regarding malaria vaccine   
(2) What consideration is being given and what plan is the government making regarding 
possible adoption for the country? 
(3) In the adoption of an intervention such as malaria vaccine, what are the issues and factors 
the government will like to be addressed or considered in the decision – making process 
towards possible adoption?  
(4) What are the factors (challenges, facilitating factors, and opportunities) that can drive a 
future policy process for a malaria vaccine in Tanzania?  
(5) The Tanzanian government adopted the use of ACT as 1st line drug for uncomplicated malaria 
could you highlight the decision- making process that informed its adoption. 
Prompt 
- Who were the stakeholders involved?  
- What is the line of communication?  
- What documents were referred to in the process 
- Who would you say were key to the decision making? 
- What is the process of dissemination of the decision? 
(6) Is there is a specific guideline the government uses for decision- making for the adoption of 
new health interventions? 
- Who are the key players in  the policy and decision making arenas 
- What is the role of these key players  
(7) I would also like to know the decision making process for the decision making process for 
adopting interventions such as the - IPTp; ITN, HMM, AMFM,-  in Tanzania. 
(8) What is the current malaria control strategic plan and how are they integrated into the 
National health sector planning and budget? 
(9)  What are the lessons learnt from adopting these new interventions i.e that can help foresee 
possible enabling and constraints for a decision on the malaria vaccine – RTS,S.     
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Landscape Analysis of National Policy Decision Process for Adopting the RTSS vaccine  – Tanzania 
Interview guide for Division Vaccines and Immunization (DVI) [NPI] 
Introduction  
For the purpose of this interview, we will like to focus on the 2 major vaccines (newly) 
introduced/adopted in Tanzania –  
Vaccine (1) Hib and PCV (2) CSM. 
(1) In the adoption of this vaccine (1) & (2) what where the issues /factors considered in the 
decision-making process? 
a. What information will you require to assist in decision-making process to adopt any 
new vaccine? 
(2) What is the adoption process for new vaccine (1) & (2) and the implications of this process 
for the RTSS malaria vaccine? 
(3) What are the factors that influence adoption? 
a. In what ways does price/cost come into decision making? 
b. How does the vaccine schedule influence decision making e.g. through routine EPI 
schedules or non-EPI schedules  
(4) Does the country have National Immunization Technical Advisory Group (NITAG)? 
a. Who is the contact person in this group? And how does this group influence the 
decision making for adoption of any new vaccine. How should they be involved? 
(5)  Is there a specific guideline the government uses for decision-making for the adoption of 
new vaccine? 
- Who are the key players in the policy and decision –making arena 
- What are the roles of the key players 
(6) To what extent is the current immunization programme strategic plan integrated within the 
national health sector planning and budgeting? 
(7) What in your opinion is the strength of the existing immunization programme vis a vis the 
adoption of new vaccine especially malaria vaccine 
(8) The country is in the process of adopting HPV vaccine; could you describe the process so far, 
the challenges, facilitating factors and opportunities? 
- How does the programme plan to scale up the intervention? 
(9) What do you think are the challenges, facilitating factors and opportunity that can direct a 
future policy process for a malaria vaccine?    
(10) What would you advice should be considered or foreseen (enabling factors and constraints) 
for a decision on malaria vaccine – RTS, S? 
(11) The government recently embarked on the process to adopt HPV vaccine for control of 
cervical cancer prevention in the Tanzania;   
- At what stage is the adoption process for HPV vaccine in Tanzania? 
- Could you share with us the adoption process so far and prior to actual pilot testing on 
going? 
- What is the strength given to WHO recommendation in the decision making process? 
(12) How did the government come to decide to adopt the vaccine 
-  What is the pathway for decision –making with regard to HPV vaccine? 
- What are the factors taking into consideration in the decision making process? 
- Explain in details each factors eg. For cost- in what ways does cost come into decision 
making; relativeness of price to other countries, same as GAVI, good price etc  
- Who are the key players in the decision-making process and what are their roles? 
(13) What documents were key to initiating the process of considering HPV vaccine? E.g BOD data 
source and docs,  
(14) What is the planned budget/finance and procurement mechanism?  
(15) What it the consideration given to existing immunization programme in the decision-making 
for the adoption of HPV?  
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- Does the schedule of HPV fit into the existing routine immunization programme? 
- What is the framework for decision-making on HPV vaccine, if there is any? 
 
Landscape Analysis of National Policy Decision Process for Adopting New Malaria Control 
Intervention and New Vaccines – Tanzania  
Interview guide for other stakeholder/policy maker [Policy unit WHO, UNICEF, Global fund, EU, other 
stakeholders] 
1. What in your opinion do you think should be the pathway/framework for decision-
making towards adoption of malaria vaccine by the country?  
2. What is your contribution to /role in the decision-making process for adoption of 
vaccines [other health interventions] in Tanzania? – adoption and procurement of 
vaccines 
3. What was your contribution to the recent adoption of Hib and PCV vaccines by Tanzania? 
Were you satisfied and how much more would you have liked to be involved and in what 
ways? 
4. What in your opinion is the strength of the existing immunization programme vis a vis 
the adoption of new vaccine especially malaria vaccine? Eg is the structure strong 
enough? If yes why and if no what infrastructure need to be put in place? 
5. Is there a specific guideline for decision-making you will like to suggest for the adoption 
of malaria vaccine?  
6. What do you think are the challenges, facilitating factors and opportunities that can 
direct a future policy process for a malaria vaccine?  
7. What would you advise should be considered or foreseen (enabling factors and 
constraints) for a decision on malaria vaccine –RTS,S? 
 
Landscape Analysis of National Policy Decision Process for Adopting New Malaria Control 
Intervention and New Vaccines – Tanzania  
Interview guide for other stakeholder/policy maker [stakeholders – Ministry of finance and procuring 
officers ] 
 
8. What in your opinion do you think should be the pathway/framework for decision-
making towards adoption of malaria vaccine by the country?  
9. What is your contribution to /role in the decision-making process for adoption of 
vaccines [other health interventions] in Tanzania? – adoption and procurement of 
vaccines 
10. What was your contribution to the recent adoption of H. Influenza type b vaccine (Hib) 
and Pneumococcal conjugate vaccines (PCV) by Tanzania? 
11. What is the consideration given to finance, budgeting and procurement in regard to 
adoption of new vaccines and other health interventions? 
a. State in what ways does each factor come into decision-making? 
12. What is the budgeting and financing mechanism available for adoption on new vaccines 
in Tanzania? 
13. What concern do you have on the sustainability especially with cost? 
14. What threshold is used to judge whether any health intervention hold be funded e.g GDP 
per capita per DALY i.e specific cost-effectiveness threshold  
15. What in your opinion is the strength of the existing immunization programme vis a vis 
the adoption of new vaccine especially malaria vaccine? Eg is the structure strong 
enough? If yes why and if no what infrastructure need to be put in place? 
16. Is there a specific guideline for decision-making you will like to suggest for the adoption 
of malaria vaccine?  
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17. What do you think are the challenges, facilitating factors and opportunities that can 
direct a future policy process for a malaria vaccine?  
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